

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00	A1	(11) International Publication Number: WO 97/14790 (43) International Publication Date: 24 April 1997 (24.04.97)
(21) International Application Number: PCT/US96/16637 (22) International Filing Date: 18 October 1996 (18.10.96) (30) Priority Data: 60/005,698 19 October 1995 (19.10.95) US (71) Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). (72) Inventors: DULAC, Catherine; Apartment 48, 10 Dewolfe Street, Cambridge, MA 02138 (US). AXEL, Richard; Apartment 62, 435 Riverside Drive, New York, NY 10025 (US). (74) Agent: WHITE, John, P.; Cooper & Dunham L.L.P., 1185 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>This is full prior art to the Harver's application (102(a))</i>
(54) Title: CLONING OF VERTEBRATE PHEROMONE RECEPTORS AND USES THEREOF (57) Abstract This invention provides an isolated nucleic acid molecule encoding a vertebrate pheromone receptor. This invention also provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of the nucleic acid molecule which encodes a pheromone receptor. This invention provides a vector which comprises the above-described isolated nucleic acid molecule. This invention also provides a purified, vertebrate pheromone receptor. This invention provides an antibody capable of specifically binding to a vertebrate pheromone receptor. The invention further provides methods for identifying ligands capable of affecting the activity of a pheromone receptor. This invention provides different uses of the identified ligands. This invention also provides a transgenic nonhuman living organism expressing a pheromone receptor.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

CLONING OF VERTEBRATE PHEROMONE RECEPTORS
AND USES THEREOF

5

This application claims the benefit of U.S. Provisional Application No. 60/005,698, filed October 19, 1995, the content of which is incorporated into this application by reference.

10

The invention disclosed herein was made with Government support under NIH Grant No. NS 29832-04 from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

15

Background of the Invention

Throughout this application, various references are referred to by abbreviation. Disclosures of these publications in their entireties are hereby incorporated by references into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the claims.

In mammals, olfactory sensory perception is mediated by two anatomically and functionally distinct sensory organs: the main olfactory epithelium (MOE) and the vomeronasal organ (VNO). Pheromones activate the VNO and elicit a characteristic array of innate reproductive and social behaviors, along with dramatic neuroendocrine responses. Differential screening of cDNA libraries constructed from single sensory neurons from the rat VNO has led to the isolation of a family of about 30 putative receptor genes. Sequence analysis indicates that these genes comprise a novel family of seven transmembrane

- 2 -

domain proteins unrelated to the receptors expressed in the MOE. Moreover, the expression of each member of the gene family is restricted to a small subpopulation of VNO neurons. These genes encode mammalian pheromone
5 receptors.

Sensory systems receive information from the environment and transmit these signals to higher cortical centers in the brain where they are processed to provide an internal
10 representation of the external world. Mammals possess an olfactory system of enormous discriminatory power. Humans, for example, are capable of recognizing thousands of discrete odors. The perception of odors in humans is often viewed as an aesthetic sense, a sense capable of
15 evoking emotion and memory leading to measured thoughts and behaviors. Smell, however, is also the primal sense. In most species, odors can elicit innate and stereotyped behaviors that are likely to result from the nonconscious perception of odors. These different pathways of
20 olfactory sensory processing are thought to be mediated by two anatomically and functionally distinct olfactory sensory organs, the main olfactory epithelium (MOE) and the vomeronasal organ (VNO) (Figure 1).

25 In mammals, the sensory epithelium of the main olfactory system resides within the posterior recess of the nasal cavity, whereas the vomeronasal organ resides more anteriorly in a blind-ended pouch within the septum of the nose (Jacobson, 1811; see also Halpern, 1987;
30 Wysocki, 1989; and Farbman, 1992 for reviews). The sensory neurons of both the MOE and VNO are bipolar. The dendrites terminate in specialized microvilli or cilia that bind odorants and transduce specific odorant binding into neural activity. The axons from sensory neurons of
35 the MOE project through the skull to the main olfactory

- 3 -

bulb, the first relay station in the brain. The main olfactory bulb then sends most of its fibers to the olfactory cortex which in turn projects to higher sensory centers. The vomeronasal system, however, transmits
5 olfactory information via a separate pathway of neuronal projections. The neurons of the VNO send axons to the accessory olfactory bulb which projects to a discrete locus within the amygdala distinct from the zone that receives fibers from the main olfactory pathway
10 (Broadwell, 1975; Scalia and Winans, 1975; Winans and Scalia, 1970). The vomeronasal nucleus in the amygdala, in turn, sends fibers directly to the hypothalamus (Kevetter and Winans, 1981; Krettek and Price, 1977; 1978). Thus, the VNO pathway bypasses higher cognitive
15 centers resulting in innate and stereotyped behavioral and neuroendocrine responses.

What chemical signals activate the VNO and what responses do they elicit? The VNO is largely responsive to
20 olfactory cues secreted by other individuals within a species. These chemical signals provide information about gender, dominance, or reproductive status and elicit innate social and sexual behaviors, along with profound neuroendocrine changes (reviewed in Halpern,
25 1987; Wysocki, 1989; Wysocki and Lepri, 1991). In male rodents, for example, removal of the vomeronasal organ in virgin animals severely impairs sexual responses resulting in a dramatic reduction in the frequency of mating (Clancy et al., 1984; Meredith, 1986). In female
30 rodents, activation of the VNO can induce puberty and estrus in the presence of males and prevent estrus in group-housed females (Lomas, 1982; Johns et al., 1978; Reynolds and Keverne, 1979). Similarly, lesions in the vomeronasal system dramatically diminish male-specific
35 aggressive behaviors (Bean, 1982; Clancy et al., 1984).

- 4 -

The chemical signals responsible for eliciting these behaviors have been broadly defined as pheromones. Two classes of steroids, 16-androstenes and estrogens can elicit reproductive behaviors in some mammals (Melrose et al., 1971; Michael and Keverne, 1968); F-prostaglandins and steroids elicit sperm production and mating in fish (Stacey and Sorensen, 1986; Sorensen et al., 1988) and small fatty acids in association with the protein, aphrodisin, have been implicated in the male sexual response in hamsters (Henzel, et al., 1988; Singer, 1991). In most instances however, the chemical nature of the odorants responsible for innate behavioral responses has not been elucidated.

Neither the pheromone receptors nor the signal transduction pathways activated by pheromone in vomeronasal neurons have been identified. In the MOE, the repertoire of odorant receptor genes consists of about 1,000 genes, each encoding a distinct seven transmembrane domain protein (Buck and Axel, 1991; Parmentier et al., 1992; Ben Arie et al., 1994). Analysis of the expression patterns of this family of odorant receptor genes (Ngai et al., 1993; Ressler et al., 1993; Vassar et al., 1993; Vassar et al., 1994; Ressler et al., 1994) , coupled with earlier electrophysiologic and tracing experiments (Kauer et al., 1987; Stewart et al., 1979; Lancet et al., 1982; Mori et al., 1992; Imamura et al., 1992; Katoh et al., 1993) have provided a logic for olfactory discrimination. Individual sensory neurons in the MOE are likely to express only one of the thousand receptor genes (Ngai et al., 1993; Chess et al., 1994; C. Dulac and R. Axel, unpublished studies). Neurons expressing a given receptor, although randomly distributed in domains of the epithelium, project their axons to a small number of

- 5 -

topographically fixed loci (or glomeruli) in the main olfactory bulb (Vassar et al, 1994; Ressler et al., 1994). These data support a model of olfactory coding in which discrimination of odor quality would result from the detection of specific spatial patterns of activity in the olfactory bulb.

The isolation of the genes encoding the pheromone receptors from VNO neurons might similarly provide insight into the chemical nature of the pheromones themselves, the logic of olfactory coding in the VNO, and the way in which perception of this class of odors leads to innate behaviors. Applicants' efforts to identify the genes encoding the mammalian pheromone receptors by virtue of potential homology with the family of odorant receptor genes expressed in the main olfactory epithelium have been unsuccessful. Applicants therefore developed a cloning strategy in which cDNA libraries were constructed from individual rat VNO neurons. Difference cloning permitted the identification of about 30 genes that define a novel family of presumed seven-transmembrane domain receptors that are evolutionarily independent of the odorant receptors of the MOE. Expression of the individual members of this gene family is restricted to a distinct set of VNO neurons such that different neurons express different receptor genes. These genes encode mammalian pheromone receptors.

- 6 -

Summary of the Invention

5 This invention provides an isolated nucleic acid molecule encoding a vertebrate pheromone receptor. This invention also provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of the above-described nucleic acid molecule.

10 This invention provides a vector which comprises the above-described isolated nucleic acid molecule. In an embodiment, the above described isolated nucleic acid molecule is operatively linked to a regulatory element. In a further embodiment, the vector is a plasmid.

15 This invention provides a host vector system for the production of a polypeptide having the biological activity of a vertebrate pheromone receptor which comprises the above-described vector and a suitable host.

20 This invention also provides a host vector system, wherein the suitable host is a bacterial cell, yeast cell, insect cell, or animal cell.

25 This invention provides a method of producing a polypeptide having the biological activity of a vertebrate pheromone receptor which comprising growing the above-described host vector system under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

30 This invention also provides a purified, vertebrate pheromone receptor.

35 This invention also provides a polypeptide encoded by the above-described isolated vertebrate nucleic acid

- 7 -

molecule.

This invention provides an antibody capable of binding to a vertebrate pheromone receptor. This invention further
5 provides an antibody capable of competitively inhibiting the binding of the antibody capable of binding to a vertebrate pheromone receptor.

This invention provides a method for identifying cDNA
10 inserts encoding pheromone receptors comprising: (a) generating a cDNA library which contains clones carrying cDNA inserts from an individual vomeronasal sensory neuron; (b) hybridizing the nucleic acid molecules of clones from the cDNA libraries generated in step (a) with
15 probes prepared from the individual vomeronasal neuron and probes from a second individual vomeronasal neuron or a main olfactory epithelium neuron; (c) selecting clones which hybridized with probes from the individual vomeronasal neuron but not from the second individual
20 vomeronasal neuron or the main olfactory epithelium neuron; and (d) isolating clones which carry the hybridized inserts, thereby identifying the inserts encoding pheromone receptors.

25 This invention also provides the above-described method wherein after step (c), further comprising: (a) amplifying the inserts from the selected clones by polymerase chain reaction; (b) hybridizing the amplified inserts with probes from the individual vomeronasal
30 neuron; and (c) isolating the clones which carry the hybridized inserts, thereby identifying the inserts encoding the pheromone receptors. This invention also provides cDNA inserts identified by the above methods.

35 This invention also provides a method for identifying DNA

- 8 -

inserts encoding pheromone receptors comprising: (a) generating DNA libraries which contain clones carrying inserts from a sample containing vomeronasal sensory neuron(s); (b) contacting clones from the cDNA libraries generated in step (a) with nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of a pheromone receptor in appropriate conditions permitting the hybridization of the nucleic acid molecules of the clones and the nucleic acid molecule; (c) selecting clones which hybridized with nucleic acid molecule; and (d) isolating the clones which carry the hybridized inserts, thereby identifying the inserts encoding the pheromone receptors. In an embodiment, the sample only contain an individual vomeronasal sensory neuron.

This invention also provides a method to identify DNA inserts encoding pheromone receptors comprising: (a) generating DNA libraries which contain clones with inserts from a sample containing vomeronasal sensory neuron(s); (b) contacting the clones from the DNA libraries generated in step (a) with appropriate polymerase chain reaction primers capable of specifically binding to nucleic acid molecules encoding pheromone receptors in appropriate conditions permitting the amplification of the hybridized inserts by polymerase chain reaction; (c) selecting the amplified inserts; and (d) isolating the amplified inserts, thereby identifying the inserts encoding the pheromone receptors.

This invention also provides DNA inserts identified by the above methods.

This invention provides a method to isolate DNA molecules encoding pheromone receptors comprising: (a) contacting

- 9 -

a biological sample known to contain nucleic acids with appropriate polymerase chain reaction primers capable of specifically binding to nucleic acid molecules encoding pheromone receptors in appropriate conditions permitting the amplification of the hybridized molecules by polymerase chain reaction; (b) isolating the amplified molecules, thereby identifying the DNA molecules encoding the pheromone receptors. This invention also provides the nucleic acid molecules isolated by the above method.

10

This invention provides a method of transforming cells which comprises transfecting a host cell with a suitable vector comprising a nucleic acid molecule encoding a pheromone receptor as described above. This invention also provides transformed cells produced by above method.

15

The invention also provides transformed cells wherein the host cells are not usually expressing pheromone receptors and transformed cells wherein the host cells are expressing pheromone receptors.

20

This invention provides a method of identifying a compound capable of specifically binding to a vertebrate pheromone receptor which comprises contacting a transfected cells or membrane fractions of the above transfected cells with an appropriate amount of the compound under conditions permitting binding of the compound to such receptor, detecting the presence of any such compound specifically bound to the receptor, and thereby determining whether the compound specifically binds to the receptor.

25

30

This invention provides a method of identifying a compound capable of specifically binding to a vertebrate pheromone receptor which comprises contacting an

35

- 10 -

appropriate amount of the purified pheromone receptor with an appropriate amount of the compound under conditions permitting binding of the compound to such purified receptor, detecting the presence of any such compound specifically bound to the receptor, and thereby determining whether the compound specifically binds to the receptor.

This invention also provides a method of identifying a compound capable of activating the activity of a pheromone receptor which comprises contacting the transfected cells or membrane fractions of the above described transfected cells with the compound under conditions permitting the activation of a functional pheromone receptor response, the activation of the receptor indicating that the compound is capable of activating the activity of a pheromone receptor.

This invention provides a method of identifying a compound capable of activating the activity of a pheromone receptor which comprises contacting a purified pheromone receptor with the compound under conditions permitting the activation of a functional pheromone receptor response, the activation of the receptor indicating that the compound is capable of activating the activity of a pheromone receptor.

This invention provides a method of identifying a compound capable of inhibiting the activity of a pheromone receptor which comprises contacting the transfected cells or membrane fractions of the above described transfected cells with an appropriate amount of the compound under conditions permitting the inhibition of a functional pheromone receptor response, the inhibition of the receptor response indicating that the

- 11 -

compound is capable of inhibiting the activity of a pheromone receptor.

5 This invention provides a method of identifying a compound capable of inhibiting the activity of a pheromone receptor which comprises contacting an appropriate amount of the purified pheromone receptor with an appropriated amount of the compound under conditions permitting the inhibition of a functional
10 pheromone receptor response, the inhibition of the receptor response indicating that the compound is capable of activating the activity of a pheromone receptor. In an embodiment of the above method, the purified receptor is embedded in a lipid bilayer.

15 This invention also provides compounds identified by the above methods. This invention further provides a pharmaceutical composition comprising an effective amount of the identified compound and a pharmaceutically acceptable carrier.
20

This invention provides a method for manipulating the maternal behavior of a female subject comprising administering effective amount of the above compound to
25 the female subject. In an embodiment, the female subject is a human.

This invention provides a method for manipulating the social behavior of a subject comprising administering effective amount of the above compound to the subject.
30 In an embodiment, the subject is a human. In another embodiment, the subject is an animal.

This invention provides a method for manipulating the reproductive functions of an animal comprising
35

- 12 -

administering effective amount of the above compound to the subject. This invention provides a method for manipulating the reproductive behaviors of a subject comprising administering effective amount of the above compound to the subject.

This invention provides a method for increasing the fertility of a subject comprising administering effective amount of the above compound to the subject. This invention provides a method for manipulating hormonal secretion of a subject comprising administering effective amount of the above compound to the subject.

This invention also provides a method for manipulating food intake rate of a subject comprising administering effective amount of the above compound to the subject.

The above methods of different uses of the identified compounds are applicable to different domestic animals as well as human.

This invention provides a composition for manipulating the maternal behavior of a female subject comprising effective amount of the identified compound and an acceptable carrier. This invention also provides a composition for manipulating the social behavior of a subject comprising effective amount of the identified compound and an acceptable carrier. This invention further provides a composition for manipulating the reproductive functions of a subject comprising effective amount of the identified compound and an acceptable carrier. This invention also provides a composition for changing the reproductive behavior of an animal comprising effective amount of the identified compound and an acceptable carrier. This invention provides a

- 13 -

composition for increasing the fertility of a subject comprising effective amount of the identified compound and an acceptable carrier.

5 This invention provides a composition for changing hormonal secretion of a subject comprising effective amount of the identified compound and an acceptable carrier.

10 In an embodiment, the compound is a polypeptide.

This invention provides a transgenic nonhuman living organism expressing DNA encoding a pheromone receptor, either the natural or modified form, and transgenic
15 nonhuman living organism expressing DNA encoding the polypeptide capable of activating or inhibiting the activity of a pheromone receptor.

This invention also provides a transgenic nonhuman living
20 organism comprising a homologous recombination knockout of the native pheromone receptor.

- 14 -

Brief Description of the Figures

Figure 1. Spatial segregation of the vomeronasal organ and the main olfactory systems. (A) A drawing of a parasagittal section through the skull of a rat. The convoluted turbinates of the main olfactory system (MOE) reside within the posterior recess of the nasal cavity, whereas the vomeronasal organ (VNO) resides more anteriorly in a blind-ended pouch within the septum of the nose. The axons from sensory neurons of the MOE project to the main olfactory bulb (OB), whereas the neurons of the VNO send axons to the anatomically distinct, more posteriorly-placed accessory olfactory bulb (AOB). (B) A drawing of a coronal section showing the anatomically distinct vomeronasal organ and the main olfactory epithelium. NC, nasal cavity; P, palate.

Figure 2. Identification of cDNA clones specifically expressed in an individual VNO neuron. 20 cDNA clones initially identified by differential screening of a cDNA library from a single VNO neuron were isolated. The inserts were amplified by PCR, electrophoresed on 1% agarose gels, and blotted to nylon filters. Blots were annealed with ³²P-labeled cDNA probe from VNO neuron 1 (A), VNO neuron 2 (B), or a neuron from the main olfactory epithelium (C). Two cDNA clones (18 and 19) only anneal with cDNA prepared from VNO neuron 1. One clone (17) anneals with the cDNA from both VNO neurons, but not with cDNA from an MOE neuron.

35

- 15 -

Figure 3. Expression of VN1 receptor RNA is restricted to a subset of vomeronasal neurons. Coronal sections of the vomeronasal organ dissected from adult male rats were annealed with digoxigenin-labeled, antisense RNA probes for (A) the olfactory marker protein (OMP); (B) The M12 receptor (a receptor expressed in abundance in the main olfactory epithelium) and (C) The VNO-specific receptor, VN1. (D) *In situ* hybridization of VN1 to a coronal section of turbinates from the newborn main olfactory epithelium. The arrow in B indicates a single positive VNO neuron expressing the MOE receptor, M12. In Panel A, N denotes the neuroepithelium; L, the lumen of VNO; and V the vomeronasal vein. In Panel D, the arrow points to the MOE; NC, nasal cavity. Scale bar equals 120mm

Figure 4. Deduced amino acid sequences of the pheromone receptor cDNAs. (A) The deduced amino acid sequences of seven putative pheromone receptor cDNAs, VN1, VN2, VN3, VN4, VN5, VN6, VN7 (Seq. ID. Nos.:8-14) are aligned. Predicted positions of the seven transmembrane domains are indicated (I-VII). Amino acid residues common to at least five of the seven sequences are highlighted in black. (B) An alignment between the sequences of the second and third transmembrane domains of the rat prostaglandin receptor E3 (rEP3B) (Seq. ID. No.:16), and the VNO receptor VN2 (Seq. ID. No.:17) showing 28% identity over this region of the receptor sequence. (C) An alignment between the sequences of VN6 (Seq. ID. No.:18) and HG25

- 16 -

(Seq. ID. No.:15) which is deduced from a human clone.

5 Figure 5. Southern blot analysis with the seven pheromone
receptor cDNAs. Rat genomic DNA isolated from
liver was digested with Pst1 (lanes 1) or EcoR1
(lanes 2), electrophoresed on 0.8% agarose
gels, and blotted to nylon filters. Blots were
annealed with ³²P-labeled probes corresponding to
10 the seven different receptor cDNAs, VN1-VN7
(Panels A-G, respectively). Under the high
stringency conditions of hybridization and
washing used in these experiments, cross
hybridization is observed between VN1 and VN2,
15 whereas the other individual receptor probes do
not crosshybridize. A mix of six probes
specific for each of the six receptor
subfamilies (VN2-VN7) was annealed under
conditions of high (H) and lower (I)
20 stringency to either Pst1 (lanes 1), EcoR1
(lane 2), or Hind3 (lane 3) cleaved DNA (See
Experimental Procedures). Panel I was run
separately from Panels A-H, which were
electrophoresed on the same gel.

25 Figure 6. Localization of the individual receptors to
distinct subpopulations of cells within the
vomeronasal organ. In situ hybridization to
coronal sections of a dissected VNO using
30 digoxigenin-labeled probes from either the
individual receptors, or a mix of the six
receptors. Digoxigenin-labeled antisense RNA
probes from receptor VN1 (A), receptor VN3 (C),
receptor VN4 (D), or a mix of six probes
35 specific for each receptor subfamilies (E) were

- 17 -

annealed to a coronal section of the VNO dissected from male rats. Panel B shows the annealing of receptor VN1 probe to a section through the VNO from a female rat. Panel F shows a high power magnification of (E). VNO cDNA clones 1-7 label 2.7, 3.8, 1.1, 1.2, 1.1, 1.5, and 3% of the cells in the neuroepithelium, respectively. The mix of seven probes label 15% of the cells. Scale bar equals 120 mm.

Figure 7. Receptor expression is restricted to VNO neurons. A coronal section through the head of an E17 rat shows hybridization of a mix of 6 receptor probes to neurons within the VNO (arrows), but not to neurons within the main olfactory epithelium nor to other tissues in the nose. NC, nasal cavity; S, septum. Scale bar equals 250 mm. Nucleic acid sequence of cDNA A. The underlined ATG is the initiated codon used and the underlined TAA is the termination codon used.

Figure 8. Nucleic acid sequence of VN1 (Seq. ID. No.:2).

Figure 9. Nucleic acid sequence of VN3 (Seq. ID. No.:3).

Figure 10. Nucleic acid sequence of VN4 (Seq. ID. No.:4).

Figure 11. Nucleic acid sequence of VN5 (Seq. ID. No.:5).

Figure 12. Nucleic acid sequence of VN6 (Seq. ID. No.:6).

Figure 13. Nucleic acid sequence of VN7 (Seq. ID. No.:7).

- 18 -

Figure 14. Nucleic acid sequence of hg25x (Seq. ID. No.:1).

- 19 -

Detailed Description of the Invention

5 This invention provides an isolated nucleic acid molecule encoding a vertebrate pheromone receptor. In an embodiment, the nucleic acid molecule is a DNA molecule. The DNA may be cDNA, genomic or synthetic DNA. In another embodiment, the nucleic acid is an RNA molecule.

10 In a further embodiment, the nucleic acid molecule encodes a mammalian pheromone receptor. In a still further embodiment, the nucleic acid molecule encodes a rat pheromone receptor. In another further embodiment, the nucleic acid molecule encodes a human pheromone receptor.

15 The nucleic acid molecules encoding a pheromone receptor includes molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms.

20 These molecules include but not limited to: the incorporation of codons "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate sequences that facilitate construction of readily expressed vectors. Accordingly, these changes may result

25

30

35

- 20 -

in a modified pheromone receptor. It is the intent of this invention to include nucleic acid molecules which encodes modified pheromone receptor. Also, to facilitate the expression of receptor in different host cells, it
5 may be necessary to modify the molecule such that the expressed receptors may reach the surface of the host cells. The modified pheromone receptor should have biological activities similar to the unmodified pheromone receptor. The molecules may also be modified to increase
10 the biological activity of the expressed receptor.

This invention also provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of
15 the above-described nucleic acid molecule. This nucleic acid molecule may be DNA or RNA.

This invention provides a vector which comprises the above-described isolated nucleic acid molecule.

20 In another embodiment, the vector is a plasmid. In a further embodiment, the plasmid is designated VN1 (ATCC Accession No.97294). In another embodiment, the plasmid is designated VN3 (ATCC Accession No. 97295). In a
25 separate embodiment, the plasmid is designated VN4 (ATCC Accession No.97296). In another embodiment, the plasmid is designated VN5 (ATCC Accession No.97297). In a separate embodiment, the plasmid is designated VN6 (ATCC Accession No.97298). In a still further embodiment, the
30 plasmid is designated VN7 (ATCC Accession No. 97299).

Plasmids VN1, VN3, VN4, VN5, VN6 and VN7 were made by cloning the DNA inserts which encoding a pheromone receptor into the XhoI and EcoRI sites of the plasmid
35 pBluescript. VN1, VN3, VN4, VN5, VN6 and VN7 were

- 21 -

deposited on September 27, 1995 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. The plasmids, VN1, VN3, VN4, VN5, VN6 and VN7 were accorded ATCC Accession Numbers 97294-97299.

The sequences of the DNA inserts of VN1, VN3, VN4, VN5, VN6 and VN7 were submitted to GenBank and were assigned with accession numbers U36785, U36895, U36896, U36897, U36898, and U36786 respectively. VN2 was assigned with GenBank accession number U36899.

In an embodiment, the above described isolated nucleic acid molecule is operatively linked to a regulatory element.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art, for example the methods described above for constructing vectors in general.

This invention provides a host vector system for the production of a polypeptide having the biological

- 22 -

activity of a vertebrate pheromone receptor which comprises the above-described vector and a suitable host.

5 This invention also provides a host vector system, wherein the suitable host is a bacterial cell, yeast cell, insect cell, or animal cell. The host cell of the above expression system may be selected from the group consisting of the cells where the protein of interest is normally expressed, or foreign cells such as bacterial
10 cells (such as *E. coli*), yeast cells, fungal cells, insect cells, nematode cells, plant or animal cells, where the protein of interest is not normally expressed. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CV1 cells and various
15 primary mammalian cells.

This invention provides a method of producing a polypeptide having the biological activity of a vertebrate pheromone receptor which comprising growing
20 the above-described host vector system under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

This invention also provides a purified, vertebrate
25 pheromone receptor.

This invention also provides a polypeptide encoded by the above-described isolated vertebrate nucleic acid molecule.

30 This invention provides an antibody capable of binding to a vertebrate pheromone receptor. This invention further provides an antibody capable of competitively inhibiting the binding of the antibody capable of specifically
35 binding to a vertebrate pheromone receptor. In an

- 23 -

embodiment, the antibody is monoclonal. In another embodiment, the antibody is polyclonal.

Monoclonal antibody directed to a pheromone receptor may
5 comprise, for example, a monoclonal antibody directed to
an epitope of a pheromone receptor present on the surface
of a cell. Amino acid sequences may be analyzed by
methods well known to those skilled in the art to
10 determine whether they produce hydrophobic or hydrophilic
regions in the proteins which they build. In the case of
cell membrane proteins, hydrophobic regions are well
known to form the part of the protein that is inserted
into the lipid bilayer which forms the cell membrane,
while hydrophilic regions are located on the cell
15 surface, in an aqueous environment.

Antibodies directed to a pheromone receptor may be
serum-derived or monoclonal and are prepared using
methods well known in the art. For example, monoclonal
20 antibodies are prepared using hybridoma technology by
fusing antibody producing B cells from immunized animals
with myeloma cells and selecting the resulting hybridoma
cell line producing the desired antibody. Cells such as
NIH3T3 cells or 293 cells which express the receptor may
25 be used as immunogens to raise such an antibody.
Alternatively, synthetic peptides may be prepared using
commercially available machines.

As a still further alternative, DNA, such as a cDNA or a
30 fragment thereof, encoding the receptor or a portion of
the receptor may be cloned and expressed. The expressed
polypeptide recovered and used as an immunogen.

The resulting antibodies are useful to detect the
35 presence of pheromone receptors or to inhibit the

- 24 -

function of the receptor in living animals, in humans, or in biological tissues or fluids isolated from animals or humans.

5 This antibodies may also be useful for identifying or isolating other pheromone receptor. For example, antibodies against the rat pheromone receptor may be used to screen a human expression library for a human pheromone receptor. Such antibodies may be monoclonal or
10 monospecific polyclonal antibody against a selected pheromone receptor. Human expression libraries are readily available and may be made using technologies well-known in the art.

15 This invention provides a method for identifying cDNA inserts encoding pheromone receptors comprising: (a) generating a cDNA library which contains clones carrying cDNA inserts from an individual vomeronasal sensory neuron; (b) hybridizing nucleic acid molecules of clones
20 from the cDNA libraries generated in step (a) with probes prepared from the individual vomeronasal neuron and probes from a secondary individual vomeronasal neuron or a main olfactory epithelium neuron; (c) selecting clones which hybridized with probes from the individual
25 vomeronasal neuron but not from the second individual vomeronasal neuron or the main olfactory epithelium neuron; and (d) isolating clones which carry the hybridized inserts, thereby identifying the inserts encoding pheromone receptors.

30 This invention also provides the above-described method wherein after step (c), further comprising: (a) amplifying the inserts from the selected clones by polymerase chain reaction; (b) hybridizing the amplified
35 inserts with probes from the individual vomeronasal

- 25 -

neuron; and (c) isolating the clones which carry the hybridized inserts, thereby identifying the inserts encoding the pheromone receptors. The probes used may be cDNA .

5

This invention also provides cDNA inserts identified by the above methods.

10 This invention also provides a method for identifying DNA inserts encoding pheromone receptors comprising: (a) generating DNA libraries which contain clones carrying inserts from a sample containing at least one vomeronasal sensory neuron; (b) contacting clones from the cDNA libraries generated in step (a) with nucleic acid
15 molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of a pheromone receptor in appropriate conditions permitting the hybridization of the nucleic acid molecules of the clones and the nucleic acid
20 molecule; (c) selecting clones which hybridized with nucleic acid molecule; and (d) isolating the clones which carry the hybridized inserts, thereby identifying the inserts encoding the pheromone receptors. In an embodiment, the sample contain only one individual
25 vomeronasal sensory neuron.

One means of isolating a nucleic acid molecule which encodes a pheromone receptor is to probe a libraries with a natural or artificially designed probes, using methods
30 well known in the art. The probes may be DNA or RNA. The library may be cDNA or genomic DNA.

This invention also provides a method to identify DNA inserts encoding pheromone receptors comprising: (a)
35 generating DNA libraries which contain clones with

- 26 -

inserts from a sample containing at least one vomeronasal sensory neuron; (b) contacting the clones from the DNA libraries generated in step (a) with appropriate polymerase chain reaction primers capable of specifically binding to nucleic acid molecules encoding pheromone receptors in appropriate conditions permitting the amplification of the hybridized inserts by polymerase chain reaction; (c) selecting the amplified inserts; and (d) isolating the amplified inserts, thereby identifying the inserts encoding the pheromone receptors. In an embodiment, the sample contains only one individual vomeronasal sensory neuron. In a separate embodiment of the above methods, the libraries are cDNA libraries. In another embodiment, the libraries are cDNA libraries.

The appropriate polymerase chain reaction primers may be chosen from the conserved regions of the known pheromone receptor sequences. Alternatively, the primers may be chosen from the regions which are the active sites for the binding of ligands.

This invention also provides DNA inserts identified by the above methods.

This invention provides a method to isolate DNA molecules encoding pheromone receptors comprising: (a) contacting a biological sample known to contain nucleic acids with appropriate polymerase chain reaction primers capable of specifically binding to nucleic acid molecules encoding pheromone receptors in appropriate conditions permitting the amplification of the hybridized molecules by polymerase chain reaction; (b) isolating the amplified molecules, thereby identifying the DNA molecules encoding the pheromone receptors. In an embodiment, the sample contains DNA. In another embodiment, the sample contains

- 27 -

genomic DNA.-

This invention also provides the nucleic acid molecules isolated by the above method.

5

This invention provides a method of transforming cells which comprises transfecting a host cell with a suitable vector comprising a nucleic acid molecule encoding a pheromone receptor as described above. This invention
10 also provides transformed cells produced by above method.

The invention also provides transformed cells wherein the host cells are not usually expressing pheromone receptors and transformed cells wherein the host cells are
15 expressing pheromone receptors.

This invention provides a method of identifying a compound capable of specifically binding to a vertebrate pheromone receptor which comprises contacting a
20 transfected cells or membrane fractions of the above transfected cells with an appropriate amount of the compound under conditions permitting binding of the compound to such receptor, detecting the presence of any such compound specifically bound to the receptor, and
25 thereby determining whether the compound specifically binds to the receptor.

This invention provides a method of identifying a compound capable of specifically binding to a vertebrate pheromone receptor which comprises contacting an
30 appropriate amount of the purified pheromone receptor with an appropriate amount of the compound under conditions permitting binding of the compound to such purified receptor, detecting the presence of any such
35 compound specifically bound to the receptor, and thereby

- 28 -

determining whether the compound specifically binds to the receptor.

5 In an embodiment, the purified receptor is embedded in a lipid bilayer. The purified receptor may be embedded in the liposomes with proper orientation to carry out normal functions. Liposome technology is well-known in the art.

10 This invention also provides a method of identifying a compound capable of activating the activity of a pheromone receptor which comprises contacting the transfected cells or membrane fractions of the above described transfected cells with the compound under conditions permitting the activation of a functional
15 pheromone receptor response, the activation of the receptor indicating that the compound is capable of activating the activity of a pheromone receptor.

20 This invention provides a method of identifying a compound capable of activating the activity of a pheromone receptor which comprises contacting a purified pheromone receptor with the compound under conditions permitting the activation of a functional pheromone receptor response, the activation of the receptor
25 indicating that the compound is capable of activating the activity of a pheromone receptor. In an embodiment, the purified receptor is embedded in a lipid bilayer. As discussed hereinabove, the purified receptors may be embedded in liposomes with proper orientations to carry
30 out their normal functions.

This invention provides a method of identifying a compound capable of inhibiting the activity of a pheromone receptor which comprises contacting the
35 transfected cells or membrane fractions of the above

- 29 -

described transfected cells with an appropriate amount of the compound under conditions permitting the inhibition of a functional pheromone receptor response, the inhibition of the receptor response indicating that the compound is capable of inhibiting the activity of a pheromone receptor.

This invention provides a method of identifying a compound capable of inhibiting the activity of a pheromone receptor which comprises contacting an appropriate amount of the purified pheromone receptor with an appropriated amount of the compound under conditions permitting the inhibition of a functional pheromone receptor response, the inhibition of the receptor response indicating that the compound is capable of activating the activity of a pheromone receptor. In an embodiment of the above method, the purified receptor is embedded in a lipid bilayer.

In another embodiment of the above methods, the compound used is not previously known.

This invention also provides compounds identified by the above methods. This invention further provides a pharmaceutical composition comprising an effective amount of the identified compound and a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene

- 30 -

glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.

5 Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.

10 Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

This invention provides a method for manipulating the maternal behavior of a female subject comprising administering effective amount of the above compound to the female subject. In an embodiment, the female subject is a human. In another embodiment, the subject is an animal.

20 This invention provides a method for manipulating the social behavior of a subject comprising administering effective amount of the above compound to the subject. In an embodiment, the subject is a human. In another embodiment, the subject is an animal

25

This invention provides a method for manipulating the reproductive functions of a subject comprising administering effective amount of the above compound to the subject.

30

This invention also provide a method for manipulating the reproductive behavior of a subject comprising administering effective amount of the above compound to the subject.

35

- 31 -

This invention provides a method for increasing the fertility of a subject comprising administering effective amount of the above compound to the subject.

5 This invention provides a method for manipulating hormonal secretion of a subject comprising administering effective amount of the above compound to the subject. In an embodiment, the hormone is the luteinizing hormone release hormone. In another embodiment, the hormone is
10 the luteinizing hormone. In a further embodiment, the hormone is the prolactin release hormone. In a still further embodiment, the hormone is the prolactin.

This invention also provides a method for changing food
15 intake rate of a subject comprising administering effective amount of the above compound to the subject.

The above methods of different uses of the identified compounds are applicable to different animals as well as
20 human.

This invention provides a composition for manipulating the maternal behavior of a female subject comprising effective amount of the above compound and an acceptable
25 carrier. This invention also provides a composition for manipulating the social behavior of a subject comprising effective amount of the above compound and an acceptable carrier. This invention further provides a composition for manipulating the reproductive functions of a subject
30 comprising effective amount of the above compound. This invention also provides a composition for changing the reproductive behavior of an animal comprising effective amount of the above compound. This invention provides a composition for increasing the fertility of an animal
35 comprising effective amount of the above compound and an

- 32 -

acceptable carrier. The subject may be human or animal.

This invention provides a composition for manipulating hormonal secretion of a subject comprising effective
5 amount of the above compound and an acceptable carrier. In an embodiment, the hormone is the luteinizing hormone release hormone. In another embodiment, the hormone is the luteinizing hormone. In a further embodiment, the hormone is the prolactin release hormone. In a still
10 further embodiment, the hormone is the prolactin. The subject may be human or animal.

As it is well known in the art, various carriers may be used according to this invention. For example, the
15 compound may dissolve in physiological saline for administration to animal or human.

In an embodiment, the compound is a polypeptide.

20 This invention provides a transgenic nonhuman living organism expressing DNA encoding a vertebrate pheromone receptor. This invention also provides a transgenic nonhuman living organism expressing DNA encoding the polypeptide which is capable of inhibiting the activity
25 of a pheromone receptor. In an embodiment, the living organism is a transgenic animal.

This invention also provides a transgenic nonhuman living organism comprising a homologous recombination knockout
30 of the native pheromone receptor. In an embodiment, the transgenic is an animal.

One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice
35 are mated, and the resulting fertilized eggs are

- 33 -

dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2 medium (Hogan B. et al. Manipulating the Mouse Embryo, A Laboratory Manual, Cold Spring Harbor Laboratory (1986)). DNA or cDNA encoding a pheromone receptor is purified from a vector by methods well known in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the trans-gene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a pipet puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse (a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only method for inserting DNA into the egg cell, and is used here only for exemplary purposes.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

- 34 -

Experimental Details**Experimental Strategy**

Applicants' initial efforts to identify the genes encoding the pheromone receptors were based upon the assumption that the main olfactory epithelium and the vomeronasal organ might share a common evolutionary origin such that DNA sequence homology may exist between the two receptor families. However, low stringency hybridization of MOE receptor probes to rat vomeronasal cDNA libraries, as well as polymerase chain reactions (PCR) using conserved motifs from both the family of odorant receptor genes, as well as from the superfamily of known seven transmembrane domain receptors were consistently unsuccessful. Moreover, the components of the olfactory signal transduction cascade in the main olfactory epithelium [(the olfactory-specific G-protein, G_{olf} , (Jones and Reed, 1989), the olfactory-specific adenylate cyclase (Bakalyar and Reed, 1990), and the cyclic nucleotide responsive ion channel (Dhallan et al., 1990; Ludwig et al., 1990)] were not detectable in VNO neurons by *in situ* hybridization or by screening cDNA libraries (data not shown). These observations suggested that the pheromone receptors and the signal transduction pathways which they activate might have evolved independently in the VNO and the MOE.

Applicants therefore developed a cloning procedure that made no assumptions concerning the structural class of the receptor molecules. Rather, applicants only assumed that the expression of the pheromone receptors would be restricted to the vomeronasal organ, and that individual neurons within the VNO were likely to express different receptor genes. In the main olfactory epithelium, about 1% of the mRNA in a given sensory cell encodes a given receptor (Vassar et al., 1994). However, the thousand

- 35 -

different receptor genes are each expressed in different neurons such that the frequency of a specific receptor RNA will be diluted to 0.001% of the mRNA message population. The generation of libraries from individual neurons provided an experimental solution to the problem of detecting a specific mRNA in a heterogeneous population of neurons. RT-PCR was therefore used to generate double-stranded cDNA, as well as cDNA libraries from individual vomeronasal sensory neurons. Applicants expected that the frequency of a specific receptor cDNA in libraries from single neurons would be about 1%. Differential screening of such libraries from single neurons should therefore permit the isolation of pheromone receptor genes.

In control experiments, the cDNA library prepared from a single rat VNO neuron was screened with probes for tubulin and olfactory marker protein (OMP) to determine whether these libraries accurately represent the mRNA population. The frequency of these clones suggested that the representation of a given RNA was not biased in the construction of the library (see Experimental Procedures). One thousand recombinant phages from a cDNA library prepared from VNO neuron 1 were then screened in triplicate with cDNA probes prepared from VNO neuron 1, a second VNO neuron (VNO neuron 2), and a neuron from the MOE. About 2% of the cDNA clones screened showed specific hybridization with cDNA probes from VNO neuron 1, but not with probes from VNO neuron 2 or the MOE neuron. The specificity of these cDNA clones was further examined in a more sensitive assay. The inserts from these cDNA clones were amplified by PCR and the DNA products were hybridized on Southern blots with cDNA probes from VNO neuron 1, VNO neuron 2, or from an MOE sensory neuron (Figure 2). Of 20 clones initially

- 36 -

isolated from the VNO neuron 1 cDNA library, only two (clones 18 and 19 in figure 2A) appeared to be specific to VNO neuron 1 in this more sensitive screen. These two clones represented independent isolates of an identical cDNA sequence present within the cDNA library of VNO neuron 1 at a frequency of 0.5%. This cDNA was used as a probe to isolate full-length clones from a cDNA library with larger inserts constructed with RNA prepared from several dissected vomeronasal organs. A full length clone, VN1 encodes a seven transmembrane domain receptor (see below).

The pattern of expression of this cDNA was determined by performing RNA *in situ* hybridization to sections through the rat vomeronasal organ. In cross section, a thick multicellular sensory epithelium lines half of the lumen of the vomeronasal organ (Figure 3). *In situ* hybridization demonstrates that mature VNO neurons uniformly express the olfactory marker protein (OMP) (Figure 3A). In contrast, the cDNA specific for VNO neuron 1 localized to a subpopulation of VNO neurons (Figure 3C). No hybridization was observed in the MOE (Figure 3D), or in any other neural or non-neural cells (see below).

Thus, difference cloning from libraries prepared from single neurons has allowed the isolation of a novel seven transmembrane domain receptor expressed in VNO sensory neurons.

The Sequence of Several Members of the Receptor Gene Family

Applicants observed that VN1 is expressed in about 4% of the vomeronasal sensory neurons. This suggested the existence of a gene family with individual member genes

- 37 -

expressed in different subsets of neurons. Applicants therefore used both PCR and high and low stringency hybridization to VNO cDNA libraries to identify possible members of a receptor gene family expressed in other VNO neurons (see Experimental Procedures). The sequences of seven different cDNAs obtained in this manner are aligned in Figure 4. Hydropathy analysis suggests that each of the seven sequences contain seven hydrophobic stretches that represent potential transmembrane domains. Sequence analysis suggests that these putative receptors are likely to adopt a structure similar to that of the previously characterized superfamily of seven transmembrane receptors. However, the VNO receptors do not share any of the conserved sequence motifs exhibited by members of the previously identified superfamily (Baldwin, 1993; Probst et al., 1992). One region of homology however is observed with the family of mammalian prostaglandin receptors throughout the second and third transmembrane domains (Figure 4B). Twenty-five percent identity is observed between VN2 and the rat E3 prostaglandin receptor over these two domains, but no significant sequence homology is observed in other regions of the molecule. Prostaglandins are potent pheromones eliciting mating in fish, but their role as mammalian pheromones is unknown. However, this level of homology over a small region of the protein does not permit us to argue that the receptors may recognize prostaglandins.

Overall, the seven VNO cDNA sequences share between 47% and 87% sequence identity. As observed previously for the odorant receptors from the MOE (Buck and Axel 1991), this family of VNO receptors exhibits significant divergence within the transmembrane domains, the presumed site of ligand binding (Strader et al., 1994). This

- 38 -

pattern of divergence suggests that the different members may permit the binding of different structural classes of ligands.

5 **The Size of the Gene Family**

Applicants have analyzed the size of the vomeronasal receptor gene family by performing hybridizations to genomic DNA, as well as quantitative screening of genomic libraries. The seven cDNAs that applicants have
10 characterized fall within six subfamilies as defined by the observation that no crosshybridization is observed among the different subfamilies under high stringency conditions. cDNA probes from each of the six subfamilies were then annealed to Southern blots of rat genomic DNA
15 after digestion with two different restriction endonucleases (Figure 5). The vomeronasal receptor genes analyzed thus far do not contain introns within the coding region (data not shown). Restriction cleavage was performed with endonucleases that do not cleave within
20 the cDNAs applicants have isolated such that the number of hybridizing bands will closely approximate the number of receptor genes. Probes from each of the subfamilies identified from two to eight bands in genomic DNA such that a total of about 20 bands were detected in
25 hybridizations with the six individual probes. A mix of six probes identifies about 20 bands in genomic DNA at high stringency of hybridization (Figure 5H) and more than 30 bands using less stringent conditions (Figure 5I).

30

An independent estimate of the size of the gene family was obtained by screening a genomic library. A mix of the seven cDNA clones was used as a hybridization probe under reduced stringency conditions to identify about 35
35 positive clones per haploid genome. Thus, the data from

- 39 -

Southern blotting and screens of genomic library are in accord with one another and indicate that the multigene family of vomeronasal receptors applicants have identified consists of between 30 and 40 genes.

5

The Pattern of Receptor Expression in the Vomeronasal Organ

Applicants performed *in situ* hybridization to examine the spatial pattern of receptor expression in the sensory epithelium of the VNO. The VNO consists of a blind-ended tubular structure which extends in an anterior posterior dimension within the septum. In cross section, the sensory epithelium lines the medial half of the tube and a vein surrounded by non-neuronal tissue resides more laterally (Figure 3A, and Figure 6). RNA *in situ* hybridization experiments were performed with digoxigenin-labeled RNA antisense probes from each of the six subfamilies under high stringency conditions, such that it was likely that a given probe will only detect members within its own subfamily. The results with each of the six probes were qualitatively indistinguishable. In each case, applicants observed a punctate distribution of cells expressing a given receptor RNA (Figure 6). No differences in the patterns of *in situ* hybridization were observed between males and females (Figure 6A and B). Each probe detected from about 1-4% of the VNO sensory neurons. These data contrast with hybridization patterns observed with the probe for the olfactory marker protein OMP (Figure 3A), which demonstrated uniform labeling of the VNO epithelium. Control sections hybridized with sense receptor probes revealed no specific signal (data not shown). Expression of this gene family was only observed in VNO neurons, no labelling was observed in the sensory neurons of the MOE (Figures 3D and 7). Hybridization of the M12 receptor from the MOE reveals a

} different from Buck

- 40 -

5 rare positive cell at a frequency of about 1 in 20,000 VNO neurons (Figure 3B). Finally, no expression of the VNO receptors was observed upon *in situ* hybridization to sections through brain, kidney, testes, and liver (data not shown).

Analysis of several sections through the entire VNO suggested that neurons expressing a given receptor are not topologically localized but rather are randomly distributed along the anterior-posterior axis. In cross section, however, neurons expressing the receptor family applicants have cloned are preferentially localized to the apical two thirds of the zone of OMP positive cells. Previous studies in the opossum have demonstrated that this apical zone of neurons expresses the G protein G_{12a} , whereas the more basal zone expresses G_o (Halpern et al., 1995), and a similar pattern is observed in rat (Belluscio, L., Dulac, C., and Axel, R. unpublished studies). Therefore, the expression of the family of receptors applicants have isolated may be restricted to G_{12a} positive cells. It is possible that the G_o positive cells express a more distant family of receptors.

different from Buck

25 Individual Neurons Express Different Complements of Receptors.

In the main olfactory epithelium, a given neuron is likely to express only one receptor from the family of one thousand receptor genes. Moreover, neurons expressing a given receptor project their axons to one or a small number of topographically defined glomeruli within the olfactory bulb. The regulated expression of odorant receptors assuring that only one receptor is expressed in individual olfactory neurons is an important element in the coding of olfactory information in the main olfactory system. Quantitative analysis of the in

- 41 -

situ hybridizations of the VNO receptor probes indicate that neurons within the VNO similarly express only a single receptor gene.

5 The observation that 1-4% of the VNO neurons express a given receptor subfamily suggests that each cell expresses only a subset of receptor genes. If applicants demonstrate that each of the different receptor probes hybridizes with distinct non-overlapping subpopulations
10 of neurons, this would provide evidence that neurons differ with respect to the receptors they express. Sections were annealed with probes specific for each of the six receptor subfamilies, either individually or with a mixture of six probes (Figure 6). If each receptor is
15 expressed in a distinct non-overlapping subpopulation of neurons, then the sum of the cells identified with the six probes should equal the number of cells identified with the mixed probe. In accord with this suggestion, applicants observe that the percentage of olfactory
20 neurons detected with the mixed probe (15%) is significantly greater than the percentage detected with any of the individual probes alone, and approximates the sum of the percentage of positive neurons detected with the six individual probes (12%). These values are
25 present in the legend to Figure 6. These results suggest that the six receptor subfamilies are expressed in distinct non-overlapping populations of olfactory neurons and provide support for a model in which a single sensory neuron expresses a single receptor gene.

30

Experimental Discussion

Applicants have identified a novel family of seven transmembrane domain proteins which encode the mammalian pheromone receptors. Differential screening of cDNA
35 libraries constructed from single sensory neurons

- 42 -

initially led to the isolation of a family of putative receptor genes. Each member of the gene family is expressed in a small subpopulation of neurons such that the seven putative receptor genes applicants have
5 cloned identify 15% of the cells in the VNO. The expression of this gene family is restricted to neurons within the VNO and is not observed in sensory neurons of the MOE nor in other non-neuronal cells. This array of properties is consistent with those predicted for the
10 mammalian pheromone receptors. Proof that these sequences indeed encode pheromone receptors will require the demonstration that these receptor proteins bind pheromones and are able to transduce pheromone binding into alterations in membrane potential.

15 The experimental approach employed to isolate this gene family, differential screening of a cDNA library constructed from a single neuron, may be more broadly applicable to the analysis of the specific gene
20 expression in diverse populations of cells. In the nervous system, for example, functionally distinct neurons each expressing different genes, and each projecting to different targets, are often interspersed. It has therefore been difficult to isolate RNA species
25 unique to functionally distinct subsets of neurons within a heterogeneous cell population. The ability to generate cDNA libraries from individual cells within a diverse population of neurons may permit the identification of that subset of genes which afford a cell a unique
30 identity.

How Large is the Gene Family?

The number of receptor genes expressed in the two distinct olfactory organs of mammals is likely to reflect
35 the repertoire of odors recognized by the two populations

- 43 -

of olfactory-sensory neurons. The main olfactory organ can recognize a universe of odors which define an organism's environment, whereas the VNO largely recognizes molecules distinctive to the species that define the reproductive and social status of individuals within any given species. Olfactory receptors of the MOE is encoded by a family of about 1000 genes (Buck and Axel, 1991; Parmentier et al., 1992; Ben Arie et al., 1994). Since the range of molecules detected by the VNO is thought to be far smaller than the odors detected by the MOE, applicants anticipated that the repertoire of pheromone receptors would be far smaller as well. Gene cloning and Southern blotting with genomic DNA provide an estimate of the size of the pheromone receptor repertoire. A screen of genomic libraries with a mix of probes detect approximately 35 positive clones per genome. This value is in accord with the results of genomic blot hybridization at low stringency which identifies about 30 discrete genes with the available probes. This minimum estimate of 30-35 genes clearly provides a lower limit of the size of the VNO receptor repertoire since it is likely that the seven genes applicants have cloned do not allow us to detect all the members of the pheromone receptor gene family.

In situ hybridization experiments with individual probes provide an independent estimate of the number of receptor genes expressed in the VNO. Each of the seven putative pheromone receptor genes labels about 1-4% of the vomeronasal sensory neurons, whereas a mix of the genes representing the six subfamilies detects about 15% of the VNO neurons. These data suggest that a given neuron expresses only one pheromone receptor gene. Since the six subfamily probes detect about 20 genes in the chromosome at high stringency, and label 15% of the VNO

- 44 -

neurons, applicants estimate that the repertoire of pheromone receptors may consist of about 100 distinct genes.

5 **The Relationship Between the Two Olfactory Organs**

The sequences of the odorant receptors of the MOE and the pheromone receptors of the VNO share no apparent homology, indicating that the two olfactory sensory systems of mammals have evolved independently. This
10 suggestion is in accord with the observation that the signal transduction machinery of the MOE cannot be detected in the neurons of the VNO. What is the evolutionary origin of the VNO? Pheromone-responsive neurons and neurons responsive to the more general class
15 of odorants are likely to have been present throughout vertebrate evolution. With the emergence of terrestrial forms, segregation of the two types of neurons may have occurred, generating a distinct vomeronasal organ that facilitates the access and binding of the two classes of
20 odorous ligand. Thus, terrestrial vertebrates from amphibians to mammals, including humans, retain two distinct olfactory systems, the VNO and the MOE (Bertmar, 1981; Eisthen, 1992; Potiquet, 1891; Stensaas et al., 1991; Moran et al., 1991; Garcia-Velasco and Mondragon,
25 1991).

These two functional classes of sensory neurons are also apparent in invertebrate olfactory systems. These observations immediately pose the question as to whether
30 homologs of the two different families of vertebrate olfactory receptors are present within the genome of invertebrates. Attempts to identify genes related to the large family of MOE receptors in *C. Elegans* (Bargmann, personal communication) and *Drosophila* (Amrein, H.,
35 Vosshall, L., and Axel, R., unpublished studies;

- 45 -

Carlson, J., personal communication) have thus far been unsuccessful. Several large families of seven transmembrane receptor genes expressed in subsets of *C. elegans* chemosensory neurons have recently been
5 identified (Troemel et al., 1995). However, these sequences share no homology with the mammalian receptor sequences from either the VNO or MOE. It is possible that the identification of additional families of
10 receptors will reveal a common evolutionary ancestor to the vertebrate and invertebrate olfactory systems. Alternatively, the differences in the chemical nature of the odorants and differences in the physiological consequences of odor recognition might suggest independent origins for the invertebrate and vertebrate
15 olfactory system.

The Logic of Olfactory Coding in the MOE and VNO

Analysis of the patterns of expression of receptor genes in the main olfactory system has provided significant
20 insight into mechanisms for the diversity and specificity of odor recognition in mammals. Similarly, the isolation of the pheromone receptors from the vomeronasal organ is likely to help to elucidate the logic of olfactory perception in the vomeronasal system. The initial step
25 in olfactory discrimination by the MOE requires the interaction of odorous ligands with one of the multiple seven transmembrane domain receptors on olfactory sensory neurons. Discrimination among odorants requires that the brain determine which of numerous receptors has been
30 activated. Since individual olfactory sensory neurons in the MOE are likely to express only a single receptor gene, the problem of distinguishing which receptors have been activated reduces to a problem of distinguishing which neurons have been activated.

35

- 46 -

Recent experiments demonstrate that neurons expressing a given receptor, and therefore responsive to a given odorant, project their axons to one or a small number of discrete loci or glomeruli within the olfactory bulb (Vassar et al., 1994; Ressler et al. 1994; Mombaerts et al., unpublished). The positions of specific glomeruli are topographically fixed, and are conserved in the brains of all animals within a species. These data provide physical evidence that the olfactory bulb provides a two-dimensional map that identifies which of the numerous receptors have been activated within the sensory epithelium. Such a model is in accord with previous experiments demonstrating that different odors elicit spatially defined patterns of glomerular activity in the olfactory bulb (Kauer et al., 1987; Stewart et al., 1979; Lancet et al., 1982; Mori et al., 1992; Imamura et al., 1992; Kato et al., 1993). Thus, the quality of an olfactory stimulus would therefore be encoded by the specific combination of glomeruli activated by a given odorant.

At one level, the vomeronasal system shares anatomic and physiologic features with the main olfactory system, suggesting that similar experiments with pheromone receptors might also provide insight as to how the recognition of odors by the VNO leads to the elaboration of innate behaviors. Primary olfactory sensory neurons within the vomeronasal organ project a single unbranched axon which then synapses with dendrites of mitral cells in the accessory olfactory bulb, the first relay station for vomeronasal signalling in the brain. At a molecular level, applicants have identified a family of pheromone receptor genes that encode seven transmembrane domain proteins. Individual VNO neurons are likely to express only a single receptor gene. Cells expressing a specific

- 47 -

receptor are randomly dispersed within the apical zone of the sensory epithelium. Thus, the pattern of pheromone receptor expression shares striking similarities with the expression of odorant receptors in the MOE.

5

At first glance, the anatomy and molecular organization of the VNO and MOE as well as that of the main and accessory olfactory bulb appear quite similar. There are, however, important differences. In the MOE, the mitral cells, the major output neurons of the olfactory bulb, project a primary dendrite to a single glomerulus suggesting a one-to-one correspondence between mitral cell and sensory axon, such that a given mitral cell can respond to the activation of only a single class of sensory neurons. The task of discerning which sensory neurons have been activated must therefore be accomplished by integration at higher cortical centers. Mitral cells of the accessory bulb, however, exhibit a more complex primary dendritic array allowing synapse formation with more than one glomerulus and therefore more than one class of sensory neurons (Macrides et al., 1985; Takami and Graziadei, 1991). These observations suggest that in the vomeronasal system, integration permitting the detection of a specific combination of different receptors activated by pheromones may occur in the accessory olfactory bulb.

The VNO and the main olfactory system reveal striking differences in the secondary projections to the cortex and in the responses elicited by the two sensory systems. VNO neurons project directly to the amygdala and hypothalamus leading to innate and stereotypic behavioral responses (Broadwell, 1975; Scalia and Winans, 1975; Winans and Scalia, 1970; Kevetter and Winans, 1981; Krettek and Price, 1977; 1978a). In contrast, the

- 48 -

projections from the main olfactory organ activate higher cortical centers resulting in a measured emotional or cognitive response. The projections from the vomeronasal system to the hypothalamus also control the release of luteinizing hormone release hormone (LHRH) and prolactin release hormone (PRF), increasing LH and prolactin levels both centrally and peripherally (reviewed in Keverne, 1983, Meredith and Fernandez-Fewell, 1994). In this manner, stimulation of the vomeronasal system can coordinate the activation of central neural pathways with dramatic neuroendocrine changes to elicit a characteristic array of innate reproductive and social behaviors.

The coding of olfactory information is likely to be far simpler in the vomeronasal system than in the main olfactory pathway. The receptor repertoire in the VNO is an order of magnitude smaller than in the MOE. Moreover, integration in the vomeronasal pathway is apparent in the accessory bulb and the secondary projections synapse on small number of loci in the amygdala. This is in sharp contrast to the complexity of higher cortical pathways required for processing olfactory information from the MOE. Thus, the vomeronasal system may permit the analysis of the molecular events which translate the bindings of pheromones into innate stereotypic behaviors.

Pheromone Receptors in Humans

Until recently, the VNO in humans was thought to be an atretic organ of vestigial function. Recent reports, however, identify a structurally intact vomeronasal organ in virtually all biopsy specimens examined (Moran, et al., 1991; Stensaas, et al., 1991, Garcia-Velasco and Mondragon 1991) Activation of neurons has been observed in the human VNO in response to purified components from

15 Se
173 de
12 cl
12 No
42 co
20 hu
US

30 Preparation and Screening of Single Cell cDNA Libraries

The main olfactory epithelium (MOE) and vomeronasal organs (VNO) were dissected from adult Sprague-Dawley rats. The synthesis and amplification of single cell cDNA was performed according to Brady et al., 1990 with

- 50 -

modifications. Small pieces of tissue were dissociated for 10' at 37°C in phosphate buffered saline (PBS) (without Ca^{2+} , Mg^{2+}) 0.025% trypsin, 0.75mM EDTA. After gentle trituration of the tissues in Dulbecco's modified Eagle's medium plus 10% calf serum, cells were collected by centrifugation and resuspended in ice cold PBS. The cell suspension was observed on a Leitz inverted microscope and olfactory sensory neurons were identified as bipolar neurons with an axonal process and a dendrite terminating in an olfactory knob. Isolated neurons were picked with a Leitz micromanipulator fitted with a pulled and beveled microcapillary. Single cells were seeded in thin-walled PCR reaction tubes (Perkin Elmer) containing 4 μ l of ice cold cell lysis buffer (50mM Tris-HCl (pH8.3), 75mM KCl, 3mM MgCl_2 , 0.5% NP-40, containing 80ng/ml pd(T)19-24 (Pharmacia), 5u/ml Prime Rnase Inhibitor (5'-3' Inc.), 324u/ml RNAGuard (Pharmacia) and 10 μ M each of dATP, dCTP, dGTP and dTTP). Lysis was subsequently performed for 1' at 65°C. First strand cDNA synthesis was then initiated by adding 50u Moloney murine leukemia virus- and 0.5u avian-reverse transcriptases (BRL) followed by incubation for 10' at 37°. Samples were heat-inactivated for 10' at 65° C and a poly(A) was added to the first strand cDNA product by adding an equal volume of 200mM potassium cacodylate pH7.2, 4mM CoCl_2 , 0.4mM DTT, 200 μ M dATP containing 10 units terminal transferase (Boehringer) for 15' at 37° C. Samples were heat-inactivated 10' at 65°C and the contents of each tube was brought to 100 μ l with a solution made of 10mM TrisHCl (pH8.3), 50mM KCl, 2.5mM MgCl_2 , 100 μ g/ml bovine serum albumin, 0.05% Triton X-100 and containing 1mM of dATP, dCTP, dGTP, dTTP, 10 units Taq polymerase (Perkin Elmer) and 5 μ g of the PCR primer AL1. The AL1 sequence is ATT GGA TCC AGG CCG CTC TGG ACA AAA TAT GAA TTC (T)24. PCR amplification was then performed according to the

- 51 -

following schedule : 94°C for 1', 42°C for 2' and 72°C for 6' with 10" extension per cycle for 25 cycles. Five additional units of Taq polymerase were then added before performing 25 more cycles. In this manner, PCR amplified
5 cDNA was synthesized from RNA of individual neurons.

Aliquots of single cell cDNA were run on 1% agarose gels, blotted on nylon membrane (Hybond N+, Amersham) and hybridized with several DNA probes to determine the
10 representation of specific sequences in amplified cDNA. The probes included highly expressed genes (tubulin, OMP), gene expressed at lower level (Go) as well as genes whose expression is restricted to either MOE (G_{01f}) or VNO (G_{12a}) neuron. The relative level of these genes in
15 amplified cDNA prepared from individual neurons is in accord with levels determined by either *in situ* hybridization or screening more classical cDNA libraries. These data suggest that the amplified cDNA from individual neurons contains an accurate representation of
20 sequences in mRNA.

One microgram of the cDNA prepared from VNO neuron 1 was purified by phenol/chloroform extraction, digested with EcoR1, ligated into EcoR1 predigested and
25 dephosphorylated λ ZAPII phage arms (Stratagene) and packaged according to standard procedures. The library prepared from VNO neuron 1 consisted of 5×10^4 pfus with an average insert size of 600bp. The frequency of OMP and tubulin positive plaques (0.2%) suggested that the
30 representation of a given RNA was not biased during the construction of the library.

Amplified cDNA from single cells was used as probe by reamplifying 1 μ l of neuron cDNA for 10 cycles with the
35 AL1 primer in the presence of 100 μ Ci of 32P-dCTP. One

- 52 -

thousand recombinant phages from VNO neuron 1 library were plated at low density and triplicate filters (Hybond N+, Amersham) were prehybridized at 65°C in 0.5M sodium phosphate buffer (pH7.3) containing 1% bovine serum albumin and 4% SDS. Hybridization was carried out in the same buffer and at 65° C after adding 10⁷cpm/ml of the amplified cDNA probe made from either VNO neuron 1, VNO neuron 2 or from a MOE neuron. Filters were washed three times at 65°C in 0.5% SDS and 0.5X SSC. Twenty phage plaques showing specific hybridization with the VNO neuron 1 probe were isolated. Phage inserts were amplified by PCR, run on 1% agarose gels, transferred to nylon membranes and were again hybridized with single cell cDNA probes as described above. Phages 18 and 19 contained cDNA inserts which appeared to hybridize only to VNO neuron 1 cDNA probe. Plasmids were obtained from the isolated phages by performing phagemid rescue as instructed by the manufacturer (Stratagene). DNA sequence analysis was performed on plasmid DNAs using the Sequenase system (United States Biochemical Corp).

Isolation and Analysis of Full-length cDNA Clones

Poly A+ RNA was isolated from VNOs dissected from adult male or female rats using the polyA+ isolation kit (Stratagene) according to the manufacturers instructions. cDNA libraries were prepared in the λ ZapII vector (Stratagene) according to standard procedures (Sambrook et al., 1989). 2 X 10⁵ independent recombinant phages from the male and female VNO cDNA libraries were screened under high stringency hybridization (68°C in 0.5M sodium phosphate buffer (pH7.3) containing 1% bovine serum albumin and 4% SDS) with a ³²P- labelled probe (Prime-it, Stratagene) prepared from the VNO neuron 1 specific clone 18. This allowed the isolation of two

- 53 -

full length cDNA clones, VN1 and VN2. In further screens one additional crosshybridizing cDNA clone, VN3, was obtained by low stringency hybridization (55°C in the same buffer as described above) of a mix of VN1 and VN2 probes to the VNO cDNA libraries. Conserved motifs within these cDNA clones were used to generate PCR primers which were then used to amplify additional sequences from the VNO cDNA libraries. This PCR product, along with the three cDNA clones were used as probes in further hybridizations to obtain four additional full-length cDNAs.

Southern Blotting and In Situ Hybridization Analysis

Genomic DNA prepared from Sprague-Dawley rat liver was digested with the restriction enzymes EcoR1, Pst1 or Hind3, size fractionated on 0.8% agarose gels; and blotted into nylon membrane (Sambrook et al., 1989). The membranes were cross-linked under UV light, prehybridized and hybridized in 0.5M sodium phosphate buffer (pH7.3) containing 1% bovine serum albumin and 4% SDS at either high (68° C) or low (55° C) stringency conditions. Lambda fix II genomic libraries made from human placenta (Stratagene) and Sprague Dawley rats were screened under low stringency conditions.

In situ hybridization was performed as described (Schaeren-Wiemers and Gerfin-Moser, 1993) using full-length clones VN1 to VN7 as templates to synthesize digoxigenin-labeled cRNA probes. Sequences corresponding to the BamH1-Asp718 fragment of OMP cDNA (Rogers et al., 1987) were used to synthesize a 1kb OMP probe. The sequence encompassing the transmembrane domains 3 through 7 of MOE receptor M12 was isolated by PCR.

- 54 -

References

- 5 Bakalyar, H.A., and Reed, R.R. (1990). Identification of
a specialized adenylyl cyclase that may mediate odorant
detection. *Science* 250, 1403-1406.
- 10 Baldwin, J.M. (1993). The probable arrangement of the
helices in G protein-coupled receptors. *The EMBO Journal*
12(4), 1693-1703.
- Bean, N.J. (1982). Modulation of agonistic behavior by
the dual olfactory system in male mice. *Physiol. Behav.*
29, 433-437.
- 15 Ben Arie, N., Lancet, D., Taylor, C., Khen, M., Walker,
N., Ledbetter, D.H., Carrozzo, R., Patel, K., Sheer, D.,
Lehrach, H., and North, M.A. (1994). Olfactory receptor
gene cluster on human chromosome 17: possible
duplication of an ancestral receptor repertoire. *Hum.*
20 *Mol. Gen.* 3, 229-235.
- Bertmar, G. (1981). Evolution of vomeronasal organs in
vertebrates. *Evolution* 35, 359-366.
- 25 Brady, G., Barbara, M., and Iscove, N.N. (1990).
Representative in vitro cDNA amplification from
individual hemopoietic cells and colonies. *Methods in*
Mol. Cell. Biol. 2, 17-25.
- 30 Broadwell, R.D. (1975). Olfactory relationships of the
Telencephalon and Diencephalon in the rabbit. I. An
autoradiographic study of the efferent connections of the
main and accessory olfactory bulbs *J. Comp. Neurol.* 163,
329-346.
- 35

- 55 -

- Buck, L., and Axel, R. (1991). A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. *Cell* 65, 175-187.
- 5 Halpern, M., Shapiro, L.S., and Jia, C. (1995). Differential localization of G proteins in the opossum vomeronasal system. *Brain Research* 677, 157-161.
- Chess, A., Simon, I., Cedar, H., and Axel, R. (1994).
10 Allelic inactivation regulates olfactory receptor gene expression. *Cell* 78, 823-834.
- Clancy, A.N., Coquelin, A., Macrides, F., Gorski, R.A.,
and Nobel, E.P. (1984). Sexual behavior and aggression
15 in male mice: involvement of the vomeronasal system. *J. Neurosci.* 4, 2222-2229.
- Dhallan, R.S., Yau, K.W., Schrader, K.A., and Reed, R.R.
(1990). Primary structure and functional expression of
20 a cyclic nucleotide-activated channel from olfactory neurons. *Nature* 347, 184-187.
- Eisthen, H.L. (1992). Phylogeny of the vomeronasal system and of receptor cell types in the olfactory and
25 vomeronasal epithelia of vertebrates. *Micro. Res. Tech.* 23, 1-21.
- Farbman, A.I. (1992). Cell biology of olfaction. In *Developmental and Cell Biology Series* (Cambridge
30 University Press, Canada).
- Garcia-Velasco, J. and Mondragon M. (1991). The incidence of the vomeronasal organ in 1000 human subjects and its possible clinical significance. *J. Steroid Biochem.*
35 *Molec. Biol.* 39(4B), 561-564.

- 56 -

- Halpern, M. (1987). The Organization and Function of the Vomeronasal System. *Ann. Rev. Neurosci.* 10, 325-362.
- 5 Henzel, W.J., Rodriguez, H., Singer, A.G., Stults, J.T.,
Macrides, F., Agosta, W.C., and Niall, H. (1988). The
primary structure of aphrodisin. *J. Biol. Chem.* 263(32),
16682-16687.
- 10 Imamura, K., Mataga, N., and Mori, K. (1992). Coding of
odor molecules by mitral/tufted cells in rabbit olfactory
bulb. I. Aliphatic compounds. *J. Neurophysiol.* 68, 1986-
2002.
- 15 Jacobson, L. (1811). Description anatomique d'un organe
observe dans les Mammiferes. *Ann. Mus. Hist Natn Paris*
18, 412-424.
- 20 Johns, M.A., Feder, H.H., Komisaruk, B.R., and Mayer,
A.D. (1978). Urine-induced reflex ovulation in
anovulatory rats may be a vomeronasal effect. *Nature*
272, 446-448.
- 25 Jones, D.T., and Reed, R.R. (1989). Golf: An olfactory
neuron specific G-protein involved in odorant signal
transduction. *Science* 244, 790-795.
- 30 Kato, K., Koshimoto, H., Tani, A., and Mori, K. (1993).
Coding of odor molecules by mitral/tufted cells in rabbit
olfactory bulb. II. Aromatic compounds. *J.*
Neurophysiol. 70, 2161-2175.
- 35 Kauer, J.S., Senseman, D.M., and Cohen, L.B. (1987).
Odor-elicited activity monitored simultaneously from 124
regions of the salamander olfactory bulb using a voltage-
sensitive dye. *Brain Res.* 418, 255-261.

- 57 -

- Keverne, E. B. (1983) Pheromonal influences on the endocrine regulation of reproduction. *Trends Neurosc.* 6 381-384.
- 5 Kevetter, G.A., and Winans, S.S. (1981). Connections of the corticomedial amygdala in the golden hamster. I. Efferents of the "Vomeronasal Amygdala." *J. Comp. Neurol.* 197, 81-98.
- 10 Krettek, J.E., and Price, J.L. (1977). Projections from the amygdaloid complex to the cerebral cortex and thalamus in the rat and cat. *J. Comp. Neurol.* 172, 687-722.
- 15 Krettek, J.E., and Price, J.L. (1978). Amygdaloid projections to subcortical structures within the basal forebrain and brainstem in the rat and cat. *J. Comp. Neurol.* 178, 225-254.
- 20 Lancet, D., Greer, C.A., Kauer, J.S., and Shepherd, G.M. (1982). Mapping of odor-related neuronal activity in the olfactory bulb by high resolution 2-deoxyglucose autoradiography. *Proc. Natl. Acad. Sci. USA* 79, 670-674.
- 25 Lomas, D.E., and Keverne, E.B. (1982). Role of the vomeronasal organ and prolactin in the acceleration of puberty in female mice. *J. Reprod. Fert.* 66, 101-107.
- 30 Ludwig, J., Marglit, T., Eismann, E., Lancet, D., and Kaupp, U.B. (1990). Primary structure of a cAMP-gated channel from bovine olfactory epithelium. *FEBS Lett.* 270, 24-29.
- 35 Macrides, F., Schoenfeld, T.A., Marchand, J.E., and Clancy, A. N. (1985). Evidence for morphologically,

- 58 -

neurochemically and functionally heterogeneous classes of mitral and tufted cells in the olfactory bulb. *Chemical Senses* 10(2), 175-202.

- 5 Melrose, D.R., Reed, H.C., and Patterson, R.L. (1971). Androgen steroids associated with boar odour as an aid to the detection of oestrus in pig artificial insemination. *Brit. Vet. J.* 127(10), 497-502.
- 10 Meredith, M. (1986). Vomeronasal organ removal before sexual experience impairs male hamster mating behavior. *Physiol. and Behavior* 36, 737-743.
- 15 Meredith, M., and Fernandez-Fewell, G. (1994). Vomeronasal system, LHRH, and sex behaviour. *Psychoneuroendocrinology*. 19 (5-7), 657-672.
- 20 Michael, R.P., and Keverne, E.B. (1968). Pheromones in the communication of sexual status in primates. *Nature* 218(143), 746-749.
- 25 Monti-Bloch L., Jennings-White, C., Dolberg, D. S., and Berliner, D. L. (1994). The human vomeronasal system. *Psychoneuroendocrinology*. 19 (5-7), 673-686.
- 30 Moran, D.T, Jafek, B.W., and Rowley III, J. C. (1991). The vomeronasal (Jacobson's) organ in man: ultrastructure and frequency of occurrence. *J. Steroid Biochem. Molec. Biol.* 39(4B), 545-552.
- 35 Mori, K., Mataga, N., and Imamura, K. (1992). Differential specificities of single mitral cells in rabbit olfactory bulb for a homologous series of fatty acid odor molecules. *J. Neurophysiol.* 67, 786-789.

- 59 -

- Ngai, J., Chess, A., Dowling, M.M., Necles, N., Macagno, E.R., and Axel R. (1993a). Coding of olfactory information: topography of odorant receptor expression in the catfish olfactory epithelium. *Cell* 72, 667-680.
- 5 Parmentier, M., Libert, F., Schurmans, S., Schiffmann, S., Lefort, A., Eggerickx, D. Ledent, C., Mollereau, C., Gerard, C., Perret, J., Grootgoed, A., and Vassart, G. (1992). Expression of members of the putative olfactory
- 10 receptor gene family in mammalian germ cells. *Nature* 355, 453-455.
- Potiquet, M. (1891). Le canal de Jacobson. *Rev. Laryng.* (Paris) 2, 737-753.
- 15 Probst, W.C., Snyder, L.A., Schuster, D.I., Brosius, J., and Sealfon, S.C. (1992). Sequence Alignment of the G-Protein Coupled Receptor Superfamily. In *DNA and Cell Biology*, Vol. II(1) (Mary Liebert, Inc. Publishers, NY),
- 20 pp. 1-20.
- Ressler, K.J., Sullivan, S.L., and Buck, L.B. (1993). A zonal organization of odorant receptor gene expression in the olfactory epithelium. *Cell*, 73, 597-609.
- 25 Ressler, K.J., Sullivan, S., and Buck, L.B. (1994). Information coding in the olfactory system: Evidence for a stereotyped and highly organized epitope map in the olfactory bulb. *Cell* 79, 1245-1255.
- 30 Reynolds, J., and Keverne, E.B. (1979). The accessory olfactory system and its role in the pheromonally mediated suppression of oestrus in grouped mice. *J. Reprod. Fert.* 57, 31-35.
- 35

- 60 -

- Rogers, R.E., Dasgupta, P., Gubler, U., Grillo, M., Khew-Goodall, Y., and Margolis, F.L. (1987). Molecular cloning and sequencing of a cDNA for olfactory marker protein. Proc. Natl. Acad. Sci. USA 84, 1704-1708.
- 5 Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press).
- 10 Scalia, F., and Winans, S.S. (1975). The differential projections of the olfactory bulb and accessory olfactory bulb in mammals. J. Comp. Neur. 161, 31-56.
- 15 Schaeren-Wiemers, N., and Gerlin-Moser, A. (1993). A single protocol to detect transcripts of various types and expression levels in neural tissue and cultures cells: *in situ* hybridization using digoxigenin-labeled cRNA probes. Histochemistry 100, 431-440.
- 20 Singer, A.G. (1991). A chemistry of mammalian pheromones. J. Steroid Biochem. Molec. Biol. 39(4B), 627-632.
- 25 Sorensen, P.W., Hara, T.J., Stacey, N.E., and Goetz, F.W. (1988). F prostaglandins function as potent olfactory stimulants that comprise the postovulatory female sex pheromone in goldfish. Biol. of Reproduction 39, 1039-1050.
- 30 Stacey, N.E., and Sorensen, P.W. (1986). 17a, 20b-dihydroxy-4-pregnen-3-one: a steroidal primer pheromone increasing milt volume in the goldfish, *Carassius auratus*. Can. J. Zool. 64, 2412-2417.

35

- 61 -

- Stensaas, L.J., Lavker, R.M., Monti-Bloch, L., Grossier, B.I., and Berliner, D.L. (1991). Ultrastructure of the human vomeronasal organ. *J. Steroid Biochem. Molec. Biol.* 39(4B), 553-560.
- 5 Stewart, W.B., Kauer, J.S., and Shepherd, G.M. (1979). Functional organization of rat olfactory bulb analyzed by the 2-deoxyglucose method. *J. Comp. Neurol.* 185, 715-734.
- 10 Strader, C.D., Fong, T.M., Tota, M.R., and Underwood, D. (1994). Structure and function of G protein-coupled receptors. *Annu. Rev. Biochem.* 63, 101-132.
- 15 Takami, S., and Graziadei, P.P. (1991). Light microscopic Golgi study of mitral/tufted cells in the accessory olfactory bulb of the adult rat. *J. Comp. Neurol.* 311, 65-83.
- 20 Troemel, E., Chou, J., Dwyer, N.D., Colbert, H.A., and Bargmann, C.I. (1995). Divergent seven transmembrane receptors are candidate chemosensory receptors in *C. elegans*. *Cell*, in press.
- 25 Vassar, R., Ngai, J., and Axel, R. (1993). Spatial segregation of odorant receptor expression in the mammalian olfactory epithelium. *Cell* 74, 309-318.
- 30 Vassar, R., Chao, S.K., Sitcheran, R., Nunez, J.M., Vossahl, L.B., and Axel, R. (1994). Topographic organization of sensory projections to the olfactory bulb. *Cell* 79, 981-991.
- 35 Winans, S.S., and Scalia, F. (1970). Amygdaloid nucleus: New afferent input from the vomeronasal organ.

- 62 -

Science 170, - 325-344.

Wysocki, C.J. (1989). Vomeronasal chemoreception: It's
role in reproductive fitness and physiology. In Neural
5 Control of Reproductive Function (Alan R. Liss, Inc.) pp.
545-566.

Wysocki, C.J., and Lepri. J.J. (1991). Consequences of
removing the vomeronasal organ. J. Steroid Biochem.
10 Molec. Biol. 39, 661-669.

- 63 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Dulac, Catherine
Axel, Richard

(ii) TITLE OF INVENTION: Cloning Of Vertebrate Pheromone
Receptors And Uses Thereof

(iii) NUMBER OF SEQUENCES: 18

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Cooper & Dunham LLP
(B) STREET: 1185 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: United States
(F) ZIP: 10036

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: White, John P.
(B) REGISTRATION NUMBER: 28678
(C) REFERENCE/DOCKET NUMBER: 48557

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212 278 0400
(B) TELEFAX: 212 391 0526

- 64 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 530 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAACATAAGT CCAGTTATCT ACAGGTACAG GTTGATGAGA GGCCTCTCCA TTTCCACCAC	60
CTGCCTGTTG AGTGTCTCTCC AGGCCATCAA CCTCACCCCA AGGAGCTCCC GTTTGGCAAT	120
G TTCAGAGAT CCTCACATCA CAAACCGCGT TGCTTTCTCT TGCTGTGGGT CTTCCACATA	180
TCCATTAGTG GAAGCTTCTT AGTCTCCACT CTTCCCTCCA AAAATGTTGC CTCAAATAGT	240
GTTACATTTG TCACTCAATC CTGCTCTGCT GGGCCCCTGA GTTGCTTCCT TGGGCAGACA	300
ATTTTCACAC TGATGACATT TCAGGATGTC TCCTTG CAGC TCATGGCCCC CTTCAGTGGA	360
TACATGGTGA TTCTCTTG TG CAGGCATAAC AGGCAGTCTC AGCATCTTCA TAGTATCAAC	420
CTTTCTCCAA AAGCACCCCC AGATAAAAGG GCCATCCAGA GCATTCTTTT GCTCGTGAGT	480
TTCTTTGTGT TCATGTGCCT TTTCCCATTT GCTGCCTTAA CACTTCTGTC	530

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1385 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 65 -

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTTCGGCACG AGTTCACCTG CCCTCGAATT TCAATTTGAG TAAGTGACCA GCAATGGAGT	60
ACAGAATCAG AAGATGGTTG GATCCCAGGC AGGCTGTGGG AGGAGGAACT CTGGAACCTGC	120
ATGAGGAGTT TGAGCACCTG CCATGGAGTA GCTGATCTCT GAGGACCCCT CACACAGGTC	180
CTGTGTTCTA CATCAAGTGC ATATTTTTTC TAGGATATTC ATTTCCGTAA GTCCTGAAAT	240
TACTTAATTT TTATAGGAGT TCTCATATAT GATGAATAAG AACAGCAGAC TCTACACTGA	300
TTCTAACATA AGGAATACCT TTTTCGCTGA AATTGGCATT GGAGTCTCAG CCAATAGCCT	360
CCTACTTCTC TTCAACATCT TCAAGTTAAT TTGTGGGCAG AGGTCCAGAC TCACTGACCT	420
GCCCATTTGGT CTCTTGTCCT TAATCAACTT ACTTATGCTA CTGATGACGG CATTTCATAGC	480
CACAGACACT TTTATTTCTT GGAGAGGGTG GGATGACATC ATATGTAAAT CCCTTCTCTA	540
CCTGTACAGA ACTTTTAGAG GTCTCTCTCT TTGTACCAGC TGCCTGTTGA GTGTCCTGCA	600
GGCCATCATC CTCAGTCCCA GAAGCTCCTG TTTAGCAAAG TTCAAACATA AGCCTTCCCA	660
TCACATCTCC TGTGCCATTC TTTCTCTGAG TGTCCTCTAC ATGTTCATTG GCAGTCACCT	720
CTTAGTATCC ATCATTGCCA CCCCAAATTT GACCACGAAT GACTTTATTC ATGTTACTCA	780
GTGGTGCTCT ATTCTACCCA TGAGTTACCT CATGCAAAGC ATGTTTTCTA CACTGCTGGC	840
CATCAGGGAT GTCTTTCTTA TTAGTCTCAT GGTCTGTCA ACATGGTACA TGGTGGCTCT	900
CTTGTGTAGG CACAGGAAAC AGACCCGGCA TCTTCAGGGT ACCAGCCTTT CCCCAAAGC	960
ATCCCCAGAA CAAAGGGCCA CCCGTTCCAT CCTGATGCTC ATGAGCTTAT TTGTTCTGAT	1020

- 66 -

GTCTGTCTTT GACAGCATTG TCTGCAGCTC AAGAACTATG TATCTGAATG ATCCAATATC	1080
TTATTCTTAT CAACTATTTA TGGTGCACAT CTATGCCACA GTAAGCCCTT TTGTGTTTAT	1140
TGTCAC TGAA AACATATAG TTAACTCTTT GAGGTCCATG TGTGTGAAGG TGCATGAATG	1200
TTTGAATATT CCTTGATAGC AAGCTCCATT AAGAGGAGCC AATGTAAGCA TCAGAACTGT	1260
CAATCATGGC GTGCTATGTG CTTTGGCATA TGTGAAATAT GAAGTTGTTT TTCTGTTAAA	1320
ATGATTTTACT TTAAGTGACG AGATGATGAA CGTAACAGAA GATTAAACCA CATCCCCTTT	1380
GATAT	1385

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1331 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GTGGATCCCC CGGGCTGCAG GAATTCGGCA CGAGCCGTGA TTAAGGGACT TTGAACTTTT	60
CAAGGGATTT GGAGTTTAT GAAGAATTG AAGATTTACA GAGTTTACAG GAATGGAGCT	120
GACCAGCCAC TATGACATGC CTTATATCTC CAAGAGCATA AATATAAGGC ATGGCATGAG	180
AGGACCAGCA GCCACTGTTC TCATATATGA TGAATAAGAA CAGCAGAGTC CAACTGATT	240
CTACCATAAG GAATACCTTC TCCACTGAAA TTGGCATTGG AATCTTAGCC AACAGTTTCC	300
TACTTCTCTT CCACATCTTC AAGTTTATTC GTGGACAGAG GTCCAGACTC ACTGACCTGC	360

- 67 -

CCATTGGTCT CTTGTCCCTA ATCCACCTAC TGATGCTACT GATGGGGGCA TTCATAGCCA	420
TAGACATTTT TATTTCTTGG AGGGGATGGG ATGACATCAT ATGTAAATTC CTTGTCTACT	480
TGTACAGAAG TTTTAGAGGT CTCTCTCTTT GTACCACCTG CATGTTGAGT GTCCTGCAGG	540
CCATCACCTT CAGCCCCAGA AGCTCCTGTT TAGCAAAGTT CAAACATAAG TCTCCCCATC	600
ACGTCTCCTG TGCCATTATT TCGCTGAGCA TCCTCTACAT GTTCATTAGC AGTCACCTCT	660
TAGTATCCAT CAATGCCACC CCCAATTTGA CCACGAACAA CTTTATGCAA GTTACTCAGT	720
CCTGCTACAT TATACCCTTG AGTTACCTCA TGCAAAGCAT GTTTTCTACA CTTCTGGCCA	780
TCAGAGATAT CTCTCTTATT AGTCTCATGG TCCTCTCGAC TTGTTACATG GAGGTTCTCT	840
TGTGTAGGCA CAGGAATCAG ATCCAGCATC TTCAAGGGAC CAACCTTTCC CCAAAGCAT	900
CTCCAGAACA AAGGGCCACA CAGACCATCC TGATGCTCAT GACCTTCTTT GTCCTAATGT	960
CCATTTTCGA CAGCATTGTC TCCTGTTCAA GAACTATGTA TCTGAATGAT CCAACATCTT	1020
ACTATATTCA AATATTTGTA GTGGACATCT ATGCCACAGT CAGCCCTTTT GTGTTTATGA	1080
GCACTGGAAA ACATATAGTT AACTTTTTGA AGTCCATGTG TGTGAGGGTG AAGAATGTTT	1140
GAATATTCAT TAATGGACAA GATCCTTTAA GAGGAGCCAA TGTAGTCATC AGAACTGTCA	1200
GTCATGGTGT GCTGTCTATG TGCTTTGGTA AATGTGAATC ATGAAGTTGT TTTTCTGGTA	1260
AAATGATTTA CTTTAACCAA CTCATGATTG TAAACATGTA ACAGGAGATT AAACAATATC	1320
CCCTTCGGAA A	1331

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1496 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 68 -

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATTCGGCAC GAGCAAAGGC AGGGAAGATG CTCCACTGGG ATGTCATGTC TCTATGCTCC	60
ACAGTGGAAA AGTTGTCACA TTGTACAAAC ACTAAAATTA CGAATTGCTC ACAGGCACTA	120
AAAGCTTCCT TAATCCTGTG CAGGATCTCC TCAGGTACAG AGTCCTCCTG ATACGTCTAT	180
CTGGTCAGAG GAAAGAGCTG ATCAGTCATT AACAGAGCTG ATTTGGTCCC TCCAAGGTCA	240
CATGACAAGG ACTGTATGAG AAAACCAGCA GTGACATGTC TATAGAGATC ATTCTGTGCC	300
ACACCCAGCT CCATGTTTGG TTTGTGGTAT TTGCTTCCTA TCCACATACA ATGAATAAAG	360
ACAACACACT CCATGTTGAC ACAATCATGA AAATCACTAT GTTCTCTGAA GTGAGTGTTG	420
GCATCTTAGC TAACAGTATC CTGTTTTTTG GTCACCTGTG CATGCTCCTT GGAGAGAACA	480
AGCCTAAGCC CATTCACTC TACATTGCAT CCTGTGCCCT AACACAATA ATGCTGCTTA	540
TAACTATGGG ACTCATAGCT GCTGACATGT TTATTTCTCA GGGGATATGG GATTCTACCT	600
CATGCCAGTC CTTATCTAT TTGCACAGGC TTTCGAGGGG TTTTACCCTT AGTGCTGCCT	660
GTCTGCTGAA TGTCTTTTGG ATGATCACTC TCAGTTCTAA AAAATCCTGT TTAACAAAGT	720
TTAAACATAA CTCTCCCCAT CACATCTCAG GTGCCTTTCT TCTCCTCTGT GTTCTCTACA	780
TGTGTTTTAG CAGTCACCTT ATTTTATCGA TTATTGCTAC CCCTAACTTG ACCTCAGATA	840
ATTTTATGTA TGTTACTAAG TCCTGTTTCT TTCTACCCAT GTGTTACTCC AGAACAAGCA	900
TGTTTTCCAC AACAATTGCT GTCAGGGAAG CCTTTTTTAT CGGTCTCATG GCCCTGTCCA	960
GTGGGTACCT GGTGGCTTTC CTCTGGAGAC ACAGGAAGCA GGCCAGCAT CTTACAGCA	1020

- 69 -

CCGGCCTTTC TTCAAAGTCA TCTCCAGAGC AAAGGGCCAC CGAGACCATC CTGCTGCTTA	1080
TGAGTTTCTT TGTGGTTCTC TACATTTTGG AAAATGTTGT CTTCTACTCA AGGATGAAGT	1140
TCAAGGATGG GTCAACATTG TACTGTGTCC AAATTATTGT GTCCCATAGC TATGCCACTG	1200
TCAGCTCTTT TGTGTTTATT TTCCTGAAA AGCGTATGAC TAAGATATTG AGGTCACTGT	1260
GTGCCAGAAT AATAAATAAT TGATTATTCA GTGATGGGTA TTGCCCCTTA GAATAAACCA	1320
TTACGTTGTC ATCAGAGGTT TGGGTCATGA CATAATTGGG ACATTCTCTG TCTTAAATTG	1380
ATAAATGAAA TTTTCTTTTT TCCTGTAAA ACTGTTTCCT TTGTGTGTGG ATGCCCAATA	1440
TATGAAAGAA AACTAAACAC CATGTCCTCT TACATATCCA ACCAAAAAAA AAAAAA	1496

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1053 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTTTTCCCA CCTCTTCATG CTCTTTGAAA AGAACAGATC TAAGCCCATT GATCTCTACA	60
TTGCTTTCTT ATCCTTAACC CAACTAATGC TGCTTATAAC TATTGGACTT ATAGCTGCAG	120
ACATGTTTAT GTCTCGGGGG AGATGGGATT CTACCACATG CCAGTCCCTT ATCTATTTGG	180
ACAGGCTTTT GAGGGGTTTT ACCCTTTGTG CTACCTGTCT GCTGAATGTC CTTTGGACCA	240
TCACTCTCAG TCCTAGAAGC TCCTGTTTAA CAACATTTAA ACATAAATCT CCCCATCACA	300

- 70 -

TCTCAGGTGC CTTTCTTTTC TTCTGTGTTT TCTATATATC TTTTGGCAGT CACCTCTTTT	360
TATCAACAAT TGCTACCCCC AATTGACTT CAGATAATTT TATGTATGTT ACTAAATCCT	420
GTTTATTCTT ACCCATGAGT TACTCCAGAA CAAGCATGTT TTCCACACCA ATGGCCATCA	480
GGGAAGCCCT TCTTATTGGT CTCATTGGCC TGTCCAGTGG GTACATGGTT GCTTTCTTAT	540
GGAGACACAA GAATCAGGCC CGGCATCTTC ACAGCACCAG CCTTCTTCA AAAGTGTCCT	600
CAGAGCAAAG GGCCACCAGG ACCATCATGA TTCTCATGAG CTTCTTTGTG GTTCTCTACA	660
TTTTGGAAAA TGTGTCTTC TACTCTAGGA TGACATTCAA GGATGGGTCA ATGTTCTACT	720
GTGTCCAAAT TATTGTGTCC CATAGCTATG CCACCATCAG CCCTTTTGTG TTTATTTGCA	780
CAGAAAAGCG TATAATTAAA CTTTGGGGGT CAATGTCTAG CAGAATAGTA AGTATTTGAT	840
TACTCAGTGA TGGATATGGT CCCTTAATAT AAACCAATAT GTTGTCATAA TAACTATGGA	900
TCATGACATA TTGGGGACAT TCTGTGTCTT AAATTTATAA AAAAAATTTT CTTTTTTTGT	960
GTTTAATCTG TTTCCCTTGT GTGTGGATGA TAAGTATATA AAGGGAAATT AAACAGCGTG	1020
TCCCCTCAGA TATCCAAAAA AAAAAAAAAA AAA	1053

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3076 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

- 71 -

GGGCTGCAGG AATTCGGCAC GAGTCAGAGT CCTTCCCTGC TATGTGTATC TGGAGCCAGC	60
GACTCTTCTA TGGAGAGCAG CTGTGCAGGC AGGTGGTGGA GCGGAAGAAG GCGTGCTGCT	120
GTGACATCAT CAAGATGCTG CCTAGCCCTG CGTCGCTGCT CTTCTGAGGA AGCAGGAGAC	180
TGACCCCTGT GACAATGACT TGATGAGTCA CTCTGTTGTC TACTTACCCT AGTTCTTTGT	240
CCCATACAAT GAGGAGAATC AGCACACTGT ATGGAGTTGT TGACAAGCAA GCTATATTTT	300
TCTCTGAAGT AGTCATCGGG ATCTCATTC AAGTATCCT CTTCTCTTC CACATCTTTC	360
AGTTCTTCT TGAGCGTAGG CTCCGGATCA CTGACCTGAT CATCAGTCTC TTGGCCCTCA	420
TCCACCTTGG GATGCTAACA GTCATGGGAT TCAGAGCTGT TGATATTTTT GCATCTCAGA	480
ATGTGTGGAA TGACATCAA TGCAAATCCC TTGCCACTT ACACAGACTT TTGAGGGGCC	540
TCTCTCTTG TGCTACCTGT CTGCTGAGTA TCTCCAGGC CATCACCTT AGCCCCAGAA	600
GCTCCTGTTT AGCAAAGTTC AAATATAAAT CCACACAGCA CAGCCTGTGT TCCCTTCTTG	660
TGCTCTGGGC CTTCTACATG TCCTGTGGTA CTCCTACTC CTTACCATC GTTGCTGACT	720
ACAACCTCTC TTCACGCAGT CTCATATTTG TCACTGAATC CTGCATTATT TTACCCATGG	780
ATTACATCAC CAGGGATTTA TTTTTCATAT TGGGGATATT TCGGGATGTG TCCTTCATAG	840
GTCTCATGGC CCTCTCCAGC GGGTACATGG TGGCCCTCTT GTGCAGACAC AGGAAACAGG	900
CCCAGCATCT TCACAGGACC AGCCTTTCTC CAAAAGCATC CCCAGAGCAA AGGGCCACCA	960
GGACCATCCT GTTGCTCATG AGCTTCTTTG TGTGATGTA CTGCTTGAC TGCACCATAT	1020
CCGCCTCCAG ACTTATGCAC AACGGTGAAC CAATCCACCA CAGTATTCAG ATGATGGTCT	1080
CCAATAGCTA TGCCACCCTC AGCCCTTTCG TGTTAATTGT TACTGAAAAT CGAATTAGTA	1140
GGTTTTTGAA GTCCTTGCTA GGAAGGACAG TAGATGCTTA AGTATTGAGG GGAGGCAGGC	1200
CCACTAAAGG AGCCAATATG CTAGCTACTG AATAATGAAT CCTGGCCTAG TCCTCATGCA	1260

- 72 -

ATCCTGAACA AATTAATACA TGACTCATGC TTCGTTAAAC CTGCTTCTTT TGAAATGTGT 1320
ATTACCAACA CCTGTAGATA TTTGAGTCAA ATTTCTTCAT GTGTATTTCT TCTCAGTGTC 1380
AGTAGGGGAC ATCTGTGACA CTTTCACAGA TTAGGGTAAC TTGTGCACTT ATCAATAAGC 1440
TAAAGTGTAC AGCACATTTT ACTAAGCCAA TTATCTCAAC AGTTTGTTTT CTACCCAATT 1500
AAATATGTAA ATGTTACCAC CAAAAAAAAA AAAAAAAAAA 1538

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1264 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TTGGGGTAAA ACGGCTCGAT GACTTCCACA TGTTTTGCCA TGGCAGAATC TGCTCCATGC 60
GGGACAAGAA AATCTCTTTT CTGGTCTGAC GGGCTTACTG CTGAATTCAC TGTCGGCGAA 120
GGTAAGTTGA TGACTCATGA TGAACCCTGT TCTATGGCTC CAGATGACAA ACATGATCTC 180
ATATCAGGGA CTTGTTCGCA CCTTCCCTAA CAGTATCCTG TTTTTTGCCC ACCTCTGCAT 240
GTTCTTTGAA GAGAACAGGT CTAAGCCCAT TGATCTGTGC ATTGCTTTCT TATCCTTAAC 300
CCAACTAATG CTGCTTGTA CTATGGGACT CATAGCTGCA GACATGTTTA TGGCTCAGGG 360
GATATGGGAT ATTACCACAT GCAGGTCCCT TATCTATTTT CACAGACTTT TGAGGGGTTT 420
CAACCTTTGT GCTGCCTGTC TACTGCATAT CCTTGGACC TTCACTCTCA GTCCTAGAAG 480

- 73 -

CTCCTGTTTA ACAAAGTTTA AACATAAATC TCCCCATCAC ATCTCAGGTG CCTATCTTTT	540
CTTCTGTGTT CTCTATATGT CCTTTAGCAG TCACCTCTTT GTATTGGTCA TTGCTACCTC	600
CAATTTAACC TCAGATCATT TTATGTATGT TACTCAGTCC TGCTCACTTC TACCCATGAG	660
TTACTCCAGA ACAAGCACGT TTTCCTTACT GATGGTCACC AGGGAAGTCT TTCTTATCAG	720
TCTCATGGCC CTGTCCAGTG GGTACATGGT GACTCTCCTA TGGAGGCACA AGAAGCAGGC	780
CCAGCATCTT CACAGCACCA GACTTCTTTC AAAAGCATCC CCACAGCAAA GGGCCACCAG	840
GACCATCCTG CTGCTTATGA CCTTCTTTGT GGTTTTCTAC ATTTTAGGCA CTGTTATCTT	900
CCACTCAAGG ACTAAGTTCA AGGATGGGTC AATCTTCTAC TGTGTCCAAA TTATTGTGTC	960
CCATAGCTAT GCCACTATCA GCCCATTTGT GTTTGTTTTT TCTGAAAAGC GCATAATCAA	1020
GTTTTTTAGA TCAATGTGTG GCAGAATAGT AAATACTTGA TTATTCACTG ATGAGTATGG	1080
GTCATGAATA TAGTCTAGTA AATTGTGATC AGAGTTATGG CTCATGACAT ATTAAAAACA	1140
TTCTCTAATT TAAGTTTAAC ATATAAAATT ATCTTATTTC TCTTAAATGT GTTTACTTTG	1200
TGTGTATTAA AAGTATGTAA AAGATAATTA ATCCCCAAAT ACACCTTTTT TTCAAATTAA	1260
AAAA	1264

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 315 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Arg Asp Val Phe Leu Ile Ser Leu Met Val Leu Ser Thr Trp Tyr Met
195 200 205

- 75 -

Val Ala Leu Leu Cys Arg His Arg Lys Gln Thr Arg His Leu Gln Gly
210 215 220

Thr Ser Leu Ser Pro Lys Ala Ser Pro Glu Gln Arg Ala Thr Arg Ser
225 230 235 240

Ile Leu Met Leu Met Ser Leu Phe Val Leu Met Ser Val Phe Asp Ser
245 250 255

Ile Val Cys Ser Ser Arg Thr Met Tyr Leu Asn Asp Pro Ile Ser Tyr
260 265 270

Ser Tyr Gln Leu Phe Met Val His Ile Tyr Ala Thr Val Ser Pro Phe
275 280 285

Val Phe Ile Val Thr Glu Lys His Ile Val Asn Ser Leu Arg Ser Met
290 295 300

Cys Val Lys Val His Glu Cys Leu Asn Ile Pro
305 310 315

(2)* INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Met Asn Lys Asn Ser Arg Leu His Ile Asp Ser Asn Ile Arg Asn
1 5 10 15

Thr Phe Phe Thr Glu Ile Gly Ile Gly Val Ser Ala Asn Ser Leu Leu
20 25 30

- 76 -

Leu Leu Phe Asn Ile Phe Lys Phe Ile His Gly Gln Arg Ser Arg Leu
 35 40 45

Thr Asp Leu Pro Ile Gly Leu Leu Ser Leu Ile Asn Leu Leu Met Leu
 50 55 60

Leu Ile Met Ala Cys Ile Ala Thr Asp Ile Phe Ile Ser Cys Arg Arg
 65 70 75 80

Trp Asp Asp Ile Ile Cys Lys Ser Leu Leu Tyr Leu Tyr Arg Thr Phe
 85 90 95

Arg Gly Leu Ser Leu Ser Thr Thr Cys Leu Leu Ser Val Leu Gln Ala
 100 105 110

Ile Ile Leu Ser Pro Arg Ser Ser Cys Leu Ala Lys Tyr Lys His Lys
 115 120 125

Pro Pro His His Ile Phe Cys Ala Met Leu Phe Leu Ser Val Leu Tyr
 130 135 140

Met Phe Ile Ser Ser His Leu Leu Leu Ser Ile Ile Ala Thr Pro Asn
 145 150 155 160

Leu Thr Thr Asn Asp Phe Ile His Val Ser Gln Ser Cys Ser Ile Leu
 165 170 175

Pro Met Ser Tyr Leu Met Gln Ser Met Phe Ser Thr Leu Leu Ala Ile
 180 185 190

Arg Asn Val Phe Leu Ile Ser Leu Ile Val Leu Ser Thr Trp Tyr Met
 195 200 205

Val Ala Leu Leu Cys Arg His Arg Lys Gln Thr Arg His Leu Gln Asp
 210 215 220

Thr Ser Leu Ser Arg Lys Ala Ser Pro Glu Gln Arg Ala Thr Arg Ser
 225 230 235 240

Ile Leu Met Leu Arg Ser Leu Phe Gly Leu Met Ser Ile Phe Asp Ser
 245 250 255

- 77 -

Ile Ala Ser Cys Ser Arg Thr Met Tyr Leu Asn Asp Pro Thr Ser Tyr
 260 265 270

Ser Ile Gln Leu Leu Val Val His Ile Tyr Ala Thr Val Ser Pro Phe
 275 280 285

Val Phe Met Ile Thr Glu Lys His Ile Val Asn Tyr Leu Lys Ser Met
 290 295 300

Tyr Val Arg Val Leu Asn Val
 305 310

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Met Asn Lys Asn Ser Arg Val His Thr Asp Ser Thr Ile Arg Asn
 1 5 10 15

Thr Phe Ser Thr Glu Ile Gly Ile Gly Ile Leu Ala Asn Ser Phe Leu
 20 25 30

Leu Leu Phe His Ile Phe Lys Phe Ile Arg Gly Gln Arg Ser Asp Leu
 35 40 45

Thr Asp Leu Pro Ile Gly Leu Leu Ser Leu Ile His Leu Leu Met Leu
 50 55 60

Leu Met Gly Ala Phe Ile Ala Ile Asp Ile Phe Ile Ser Trp Arg Gly
 65 70 75 80

- 78 -

Trp Asp Asp Ile Ile Cys Lys Phe Leu Val Tyr Leu Tyr Arg Ser Phe
 85 90 95

Arg Gly Leu Ser Leu Cys Thr Thr Cys Met Leu Ser Val Leu Gln Ala
 100 105 110

Ile Thr Leu Ser Pro Arg Ser Ser Cys Leu Ala Lys Phe Lys His Lys
 115 120 125

Ser Pro His His Val Ser Cys Ala Ile Ile Ser Leu Ser Ile Leu Tyr
 130 135 140

Met Phe Ile Ser Ser His Leu Leu Val Ser Ile Asn Ala Thr Pro Asn
 145 150 155 160

Leu Thr Thr Asn Asn Phe Met Gln Val Thr Gln Ser Cys Tyr Ile Ile
 165 170 175

Pro Leu Ser Tyr Leu Met Gln Ser Met Phe Ser Thr Leu Leu Ala Ile
 180 185 190

Arg Asp Ile Ser Leu Ile Ser Leu Met Val Leu Ser Thr Cys Tyr Met
 195 200 205

Glu Val Leu Leu Cys Arg His Arg Asn Gln Ile Gln His Leu Gln Gly
 210 215 220

Thr Asn Leu Ser Pro Lys Ala Ser Pro Glu Gln Arg Ala Thr Gln Thr
 225 230 235 240

Ile Leu Met Leu Met Thr Phe Phe Val Leu Met Ser Ile Phe Asp Ser
 245 250 255

Ile Val Ser Cys Ser Arg Thr Met Tyr Leu Asn Asp Pro Thr Ser Tyr
 260 265 270

Tyr Ile Gln Ile Phe Gly Val Asp Ile Tyr Ala Thr Val Ser Pro Phe
 275 280 285

Val Phe Met Ser Thr Glu Lys His Ile Val Asn Phe Leu Lys Ser Met
 290 295 300

- 79 -

Cys Val Arg Val Lys Asn Val
305 310

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 310 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Asn Lys Asp Asn Thr Leu His Val Asp Thr Ile Met Lys Ile Thr
1 5 10 15

Met Phe Ser Glu Val Ser Val Gly Ile Leu Ala Asn Ser Ile Leu Phe
20 25 30

Phe Gly His Leu Cys Met Leu Leu Gly Glu Asn Lys Pro Lys Pro Ile
35 40 45

His Leu Tyr Ile Ala Ser Leu Ser Leu Thr Gln Leu Met Leu Leu Ile
50 55 60

Thr Met Gly Leu Ile Ala Ala Asp Met Phe Ile Ser Gln Gly Ile Trp
65 70 75 80

Asp Ser Thr Ser Cys Gln Ser Leu Ile Tyr Leu His Arg Leu Ser Arg
85 90 95

Gly Phe Thr Leu Ser Ala Ala Cys Leu Leu Asn Val Phe Trp Met Ile
100 105 110

Thr Leu Ser Ser Lys Lys Ser Cys Leu Thr Lys Phe Lys His Asn Ser
115 120 125

- 80 -

Pro His His Ile Ser Gly Ala Phe Leu Leu Leu Cys Val Leu Tyr Met
 130 135 140

Cys Phe Ser Ser His Leu Ile Leu Ser Ile Ile Ala Thr Pro Asn Leu
 145 150 155 160

Thr Ser Asp Asn Phe Met Tyr Val Thr Lys Ser Cys Ser Phe Leu Pro
 165 170 175

Met Cys Tyr Ser Arg Thr Ser Met Phe Ser Thr Thr Ile Ala Val Arg
 180 185 190

Glu Ala Phe Phe Ile Gly Leu Met Ala Leu Ser Ser Gly Tyr Leu Val
 195 200 205

Ala Phe Leu Trp Arg His Arg Lys Gln Ala Gln His Leu His Ser Thr
 210 215 220

Gly Leu Ser Ser Lys Ser Ser Pro Glu Gln Arg Ala Thr Glu Thr Ile
 225 230 235 240

Leu Leu Leu Met Ser Phe Phe Val Val Leu Tyr Ile Leu Glu Asn Val
 245 250 255

Val Phe Tyr Ser Ser Arg Met Phe Lys Asp Gly Ser Thr Phe Tyr Cys
 260 265 270

Val Gln Ile Ile Val Ser His Ser Tyr Ala Thr Val Ser Ser Phe Val
 275 280 285

Phe Ile Phe Thr Glu Lys Arg Met Thr Lys Ile Leu Arg Ser Val Cys
 290 295 300

Ala Arg Ile Ile Asn Asn
 305 310

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 278 amino acids
- (B) TYPE: amino acid

- 81 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Phe Ser His Leu Phe Met Leu Phe Glu Lys Asn Arg Ser Lys Pro Ile
1 5 10 15

Asp Leu Tyr Ile Ala Phe Leu Ser Leu Thr Gln Leu Met Leu Leu Ile
20 25 30

Thr Ile Gly Leu Ile Ala Ala Asp Met Phe Met Ser Arg Gly Arg Trp
35 40 45

Asp Ser Thr Thr Cys Gln Ser Leu Ile Tyr Leu Asp Arg Leu Leu Arg
50 55 60

Gly Phe Thr Leu Cys Ala Thr Cys Leu Leu Asn Val Leu Trp Thr Ile
65 70 75 80

Thr Leu Ser Pro Arg Ser Ser Cys Leu Thr Thr Phe Lys His Lys Ser
85 90 95

Pro His His Ile Ser Gly Ala Phe Leu Phe Phe Cys Val Leu Tyr Ile
100 105 110

Ser Phe Gly Ser His Leu Phe Leu Ser Thr Ile Ala Thr Pro Asn Leu
115 120 125

Thr Ser Asp Asn Phe Met Tyr Val Thr Lys Ser Cys Ser Phe Leu Pro
130 135 140

Met Ser Tyr Ser Arg Thr Ser Met Phe Ser Thr Pro Met Ala Ile Arg
145 150 155 160

Glu Ala Leu Leu Ile Gly Leu Ile Gly Leu Ser Ser Gly Tyr Met Val

- 82 -

[illegible]

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 310 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Arg Arg Ile Ser Thr Leu Tyr Gly Val Val Asp Lys Gln Ala Ile
1 5 10 15

- 83 -

Phe Phe Ser Glu Val Val Ile Gly Ile Ser Phe Asn Ser Ile Leu Phe
 20 25 30

Leu Phe His Ile Phe Gln Phe Leu Leu Glu Arg Arg Leu Arg Ile Thr
 35 40 45

Asp Leu Ile Ile Ser Leu Leu Ala Leu Ile His Leu Gly Met Leu Thr
 50 55 60

Val Met Gly Phe Arg Ala Val Asp Ile Phe Ala Ser Gln Asn Val Trp
 65 70 75 80

Asn Asp Ile Lys Cys Lys Ser Leu Ala His Leu His Arg Leu Leu Arg
 85 90 95

Gly Leu Ser Leu Cys Ala Thr Cys Leu Leu Ser Ile Phe Gln Ala Ile
 100 105 110

Thr Leu Ser Pro Arg Ser Ser Cys Leu Ala Lys Phe Lys Tyr Lys Ser
 115 120 125

Thr Gln His Ser Leu Cys Ser Leu Leu Val Leu Trp Ala Phe Tyr Met
 130 135 140

Ser Cys Gly Thr His Tyr Ser Phe Thr Ile Val Ala Asp Tyr Asn Phe
 145 150 155 160

Ser Ser Arg Ser Leu Ile Phe Val Thr Glu Ser Cys Ile Ile Leu Pro
 165 170 175

Met Asp Tyr Ile Thr Arg His Leu Phe Phe Ile Leu Gly Ile Phe Arg
 180 185 190

Asp Val Ser Phe Ile Gly Leu Met Ala Leu Ser Ser Gly Tyr Met Val
 195 200 205

Ala Leu Leu Cys Arg His Arg Lys Gln Ala Gln His Leu His Arg Thr
 210 215 220

Ser Leu Ser Pro Lys Ala Ser Pro Glu Gln Arg Ala Thr Arg Thr Ile
 225 230 235 240

Leu Leu Leu Met Ser Phe Phe Val Leu Met Tyr Cys Leu Asp Cys Thr
245 250 255

Ile Ser Ala. Ser Arg Leu Met His Asn Gly Glu Pro Ile His His Ser
260 265 270

Ile	Gln	Met	Met	Val	Ser	Asn	Ser	Tyr	Ala	Thr	Leu	Ser	Pro	Leu	Leu
		275					280					285			

Leu Ile Val Thr Glu Asn Arg Ile Ser Arg Phe Leu Lys Ser Leu Leu
290 295 300

Gly Arg Thr Val Asp Ala
305 310

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 307 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Met Asn Pro Val Leu Trp Leu Gln Met Thr Asn Met Ile Ser Tyr
1 5 10 15

Gln Gly Leu Val Arg Thr Phe Pro Asn Ser Ile Leu Phe Phe Ala His
20 25 30

Leu Cys Met Phe Phe Glu Glu Asn Arg Ser Lys Pro Ile Asp Leu Cys
35 40 45

Ile Ala Phe Leu Ser Leu Thr Gln Leu Met Leu Leu Val Thr Met Gly
50 55 60

- 85 -

Leu Ile Ala Ala Asp Met Phe Met Ala Gln Gly Ile Trp Asp Ile Thr
65 70 75 80

Thr Cys Arg Ser Leu Ile Tyr Phe His Arg Leu Leu Arg Gly Phe Asn
85 90 95

Leu Cys Ala Ala Cys Leu Leu His Ile Leu Trp Thr Phe Thr Leu Ser
100 105 110

Pro Arg Ser Ser Cys Leu Thr Lys Phe Lys His Lys Ser Pro His His
115 120 125

Ile Ser Gly Ala Tyr Leu Phe Phe Cys Val Leu Tyr Met Ser Phe Ser
130 135 140

Ser His Leu Phe Val Leu Val Ile Ala Thr Ser Asn Leu Thr Ser Asp
145 150 155 160

His Phe Met Tyr Val Thr Gln Ser Cys Ser Leu Leu Pro Met Ser Tyr
165 170 175

Ser Arg Thr Ser Thr Phe Ser Leu Leu Met Val Thr Arg Glu Val Phe
180 185 190

Leu Ile Ser Leu Met Ala Leu Ser Ser Gly Tyr Met Val Thr Leu Leu
195 200 205

Trp Arg His Lys Lys Gln Ala Gln His Leu His Ser Thr Arg Leu Ser
210 215 220

Ser Lys Ala Ser Pro Gln Gln Arg Ala Thr Arg Thr Ile Leu Leu Leu
225 230 235 240

Met Thr Phe Phe Val Val Phe Tyr Ile Leu Gly Thr Val Ile Phe His
245 250 255

Ser Arg Thr Lys Phe Lys Asp Gly Ser Ile Phe Tyr Cys Val Gln Ile
260 265 270

Ile Val Ser His Ser Tyr Ala Thr Ile Ser Pro Phe Val Phe Val Phe
275 280 285

- 86 -

Ser Glu Lys Arg Ile Ile Lys Phe Phe Arg Ser Met Cys Gly Arg Ile
 290 295 300

Val Asn Thr
 305

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 173 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Asn Ile Ser Pro Val Ile Tyr Arg Tyr Arg Leu Met Arg Gly Leu Ser
 1 5 10 15

Ile Ser Thr Thr Cys Leu Leu Ser Val Leu Gln Ala Ile Asn Leu Thr
 20 25 30

Pro Arg Ser Ser Arg Leu Ala Arg Ser Ser His His Lys Pro Arg Cys
 35 40 45

Phe Leu Leu Leu Trp Val Phe His Ile Ser Ile Ser Gly Ser Phe Leu
 50 55 60

Val Ser Thr Leu Pro Ser Lys Asn Val Ala Ser Asn Ser Val Thr Phe
 65 70 75 80

Val Thr Gln Ser Cys Ser Ala Gly Pro Leu Ser Cys Phe Leu Gly Gln
 85 90 95

Thr Ile Phe Thr Leu Met Thr Phe Gln Asp Val Ser Leu Gln Leu Met
 100 105 110

- 87 -

Ala Pro Phe Ser Gly Tyr Met Val Ile Leu Leu Cys Arg His Asn Arg
 115 120 125

Gln Ser Gln His Leu His Ser Ile Asn Leu Ser Pro Lys Ala Pro Pro
 130 135 140

Asp Lys Arg Ala Ile Gln Ser Ile Leu Leu Leu Val Ser Phe Phe Val
 145 150 155 160

Phe Met Cys Leu Phe Pro Phe Ala Ala Leu Thr Leu Leu
 165 170

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 71 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Ser Lys Arg Lys Lys Ser Phe Leu Leu Cys Ile Gly Trp Leu Ala Leu
 1 5 10 15

Thr Asp Leu Val Gly Gln Leu Leu Thr Ser Pro Val Val Ile Leu Val
 20 25 30

Tyr Leu Ser Gln Arg Arg Trp Glu Gln Leu Asp Pro Ser Gly Arg Leu
 35 40 45

Cys Thr Phe Phe Gly Leu Thr Met Thr Val Phe Gly Leu Ser Ser Leu
 50 55 60

Leu Val Ala Ser Ala Met Ala
 65 70

- 88 -

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 74 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Gly Gln Arg Ser Arg Leu Thr Asp Leu Pro Ile Gly Leu Leu Ser Leu
1 5 10 15

Ile Asn Leu Leu Met Leu Leu Ile Met Ala Cys Ile Ala Thr Asp Ile
 20 25 30

Phe Ile Ser Cys Arg Arg Trp Asp Asp Ile Ile Cys Lys Ser Leu Leu
 35 40 45

Tyr Leu Tyr Arg Thr Phe Arg Gly Leu Ser Leu Ser Thr Thr Cys Leu
 50 55 60

Leu Ser Val Leu Gln Ala Ile Ile Leu Ser
65 70

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 89 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Lys Cys Lys Ser Leu Ala His Leu His Arg Leu Leu Arg Gly Leu Ser
1 5 10 15

Leu Cys Ala Thr Cys Leu Leu Ser Ile Phe Gln Ala Ile Thr Leu Ser
20 25 30

Pro Arg Ser Ser Cys Leu Ala Lys Ser Thr Gln His Ser Leu Cys Ser
35 40 45

Leu Leu Val Leu Trp Ala Phe Tyr Met Ser Cys Gly Thr His Tyr Ser
50 55 60

Phe Thr Ile Val Ala Asp Tyr Asn Phe Ser Ser Arg Ser Leu Ile Phe
65 70 75 80

Val Thr Glu Ser Cys Ile Ile Leu Pro Met Asp Tyr Ile Thr Arg Asp
85 90 95

Leu Phe Phe Ile Leu Gly Ile Phe Arg Asp Val Ser Phe Ile Gly Leu
100 105 110

Met Ala Leu Ser Ser Gly Tyr Met Val Ala Leu Leu Cys Arg His Arg
115 120 125

Lys Gly Ala Gln His Leu His Arg Thr Ser Leu Ser Pro Lys Ala Ser
130 135 140

Pro Glu Gln Arg Ala Thr Arg Thr Ile Leu Leu Leu Met Ser Phe Phe
145 150 155 160

Val Leu Met Tyr Cys Leu Asp Cys Thr Ile Ser Ala Ser Arg
165 170

- 90 -

What is claimed is:

1. An isolated nucleic acid molecule encoding a vertebrate pheromone receptor.
2. An isolated DNA of claim 1.
- 5 3. An isolated cDNA of claim 2.
4. An isolated genomic DNA of claim 2.
5. An isolated RNA of claim 1.
6. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a mammalian pheromone receptor.
- 10 7. An isolated nucleic acid molecule of claim 6, wherein the nucleic acid molecule encodes a rat pheromone receptor.
8. An isolated nucleic acid molecule of claim 6, wherein the nucleic acid molecule encodes a human pheromone receptor.
- 15 9. A nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with a unique sequence within the sequence of a nucleic acid molecule of claim 1, 2, 3, 4, 5, 6, 7, or 8.
- 20 10. A DNA molecule of claim 9.
11. An RNA molecule of claim 9.
12. A vector which comprises the isolated nucleic acid

- 91 -

molecule of claim 1, 2, 3, 4, 5, 6, 7 or 8.

13. An isolated nucleic acid molecule of claim 12 operatively linked to a regulatory element.

14. A plasmid of claim 12.

5 15. The plasmid of claim 14 designated VN1 (ATCC Accession No.97294).

16. The plasmid of claim 14 designated VN3 (ATCC Accession No. 97295).

10 17. The plasmid of claim 14 designated VN4 (ATCC Accession No.97296).

18. The plasmid of claim 14 designated VN5 (ATCC Accession No.97297).

19. The plasmid of claim 14 designated VN6 (ATCC Accession No.97298).

15 20. The plasmid of claim 14 designated VN7 (ATCC Accession No. 97299).

20 21. A host vector system for the production of a polypeptide having the biological activity of a vertebrate pheromone receptor which comprises the vector of claim 12 and a suitable host.

22. A host vector system of claim 21, wherein the suitable host is a bacterial cell, yeast cell, insect cell, or animal cell.

23. A method of producing a polypeptide having the

- 92 -

biological activity of a vertebrate pheromone receptor which comprising growing the host vector system of claim 22 under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

- 5 24. A purified, vertebrate pheromone receptor.
25. A polypeptide encoded by the isolated vertebrate nucleic acid molecule of claim 1.
26. An antibody capable of specifically binding to a vertebrate pheromone receptor.
- 10 27. An antibody capable of competitively inhibiting the binding of the antibody of claim 26.
28. A monoclonal antibody of claim 26 or 27.
29. A method for identifying cDNA inserts encoding pheromone receptors comprising:
- 15 (a) generating a cDNA library which contains clones carrying cDNA inserts from an individual vomeronasal sensory neuron;
- 20 (b) hybridizing nucleic acid molecules of the clones from the cDNA libraries generated in step (a) with probes prepared from the individual vomeronasal neuron and probes from a second individual vomeronasal neuron or from a main olfactory epithelium neuron;
- 25 (c) selecting clones which hybridized with probes from the individual vomeronasal neuron but not from the second individual vomoernasal neuron or

- 93 -

the main olfactory epithelium neuron; and

- (d) isolating clones which carry the hybridized inserts, thereby identifying the inserts encoding pheromone receptors.

5 30. A method of claim 29, after step (c), further comprising:

- (a) amplifying the inserts from the selected clones by polymerase chain reaction;
- 10 (b) hybridizing the amplified inserts with probes from the individual vomeronasal neuron; and
- (c) isolating the clones which carry the hybridized inserts, thereby identifying the inserts encoding the pheromone receptors.

15 31. A method of claim 29, wherein the probes are cDNA probes.

32. A method of claim 30, wherein the probes are cDNA probes.

33. The cDNA inserts identified by the method of claim 29, 30, 31 or 32.

20 34. A method for identifying DNA inserts encoding pheromone receptors comprising:

- (a) generating DNA libraries which contain clones carrying inserts from a sample which contain at least one vomeronasal sensory neuron;

- 94 -

- 5 (b) contacting clones from the cDNA libraries generated in step (a) with nucleic acid molecule of claim 9, 10, or 11 in appropriate conditions permitting the hybridization of the nucleic acid molecules of the clones and the nucleic acid molecule;
- (c) selecting clones which hybridized with the nucleic acid molecule; and
- 10 (d) isolating the clones which carry the hybridized inserts, thereby identifying the inserts encoding the pheromone receptors.
35. A method of claim 34, wherein the sample contains only one individual vomeronasal sensory neuron.
- 15 36. A method to identify DNA inserts encoding pheromone receptors comprising:
- (a) generating DNA libraries which contain clones with inserts from a sample which contains at least one vomeronasal sensory neuron;
- 20 (b) contacting the clones from the DNA libraries generated in step (a) with appropriate polymerase chain reaction primers capable of specifically binding to nucleic acid molecules encoding pheromone receptors in appropriate conditions permitting the amplification of the hybridized inserts by polymerase chain reaction;
- 25 (c) selecting the amplified inserts; and
- (d) isolating the amplified inserts, thereby

- 95 -

identifying the inserts encoding the pheromone receptors.

37. A method of claim 36, wherein the sample contains only one individual vomeronasal sensory neuron.
- 5 38. A method of claim 34, wherein the libraries are cDNA libraries.
39. A method of claim 36, wherein the libraries are cDNA libraries.
- 10 40. A method of claim 34, wherein the libraries are genomic DNA libraries.
41. A method of claim 36, wherein the libraries are genomic DNA libraries.
42. DNA inserts identified by the method of claim 34, 35, 36, 37, 38, 39, 40 or 41.
- 15 43. A method to isolate DNA molecules encoding pheromone receptors comprising:
- 20 (a) contacting a biological sample known to contain nucleic acids with appropriate polymerase chain reaction primers capable of specifically binding to nucleic acid molecules encoding pheromone receptors in appropriate conditions permitting the amplification of the hybridized molecules by polymerase chain reaction;
- 25 (b) isolating the amplified molecules, thereby identifying the DNA molecules encoding the pheromone receptors.

- 96 -

44. A method of claim 43, wherein the nucleic acid contained in the sample is DNA.
45. A method of claim 44, wherein the nucleic acid contained in the sample is genomic DNA.
- 5 46. The nucleic acid molecules isolated by method of claim 43, 44 or 45.
- 10 47. A method of transforming cells which comprises transfecting a host cell with a suitable vector of claim 12.
48. Transformed cells produced by the method of claim 47.
49. The transformed cells of claim 48, wherein the host cells are not usually expressing pheromone receptors.
- 15 50. The transformed cells of claim 48, wherein the host cells are expressing pheromone receptors.
- 20 51. A method of identifying a compound capable of specifically bind to a vertebrate pheromone receptor which comprises contacting a transfected cells or membrane fractions of the transfected cells of claim 48 with an appropriate amount of the compound under conditions permitting binding of the compound to such receptor, detecting the presence of any such compound specifically bound to the receptor, and thereby determining whether the compound specifically binds to the receptor.
- 25 52. A method of identifying a compound capable of specifically bind to a vertebrate pheromone receptor which comprises contacting an appropriate amount of the

- 97 -

- 5 purified pheromone receptor of claim 24 with an appropriate amount of the compound under conditions permitting binding of the compound to such purified receptor, detecting the presence of any such compound specifically bound to the receptor, and thereby determining whether the compound specifically binds to the receptor.
53. A method of claim 52, wherein the purified receptor is embedded in a lipid bilayer.
- 10 54. A method of identifying a compound capable of activating the activity of a pheromone receptor which comprises contacting the transfected cells or membrane fractions of the transfected cells of claim 48 with the compound under conditions permitting the activation of
- 15 a functional pheromone receptor response, the activation of the receptor indicating that the compound is capable of activating the activity of a pheromone receptor.
- 20 55. A method of identifying a compound capable of activating the activity of a pheromone receptor which comprises contacting a purified pheromone receptor of claim 24 with the compound under conditions permitting the activation of a functional pheromone receptor response, the activation of the receptor indicating
- 25 that the compound is capable of activating the activity of a pheromone receptor.
56. A method of claim 55, wherein the purified receptor is embedded in a lipid bilayer.
- 30 57. A method of identifying a compound capable of inhibiting the activity of a pheromone receptor which

- 98 -

- 5 comprises contacting the transfected cells or membrane fractions of the transfected cells of claims 48 with an appropriate amount of the compound under conditions permitting the inhibition of a functional pheromone receptor response, the inhibition of the receptor response indicating that the compound is capable of inhibiting the activity of a pheromone receptor.
- 10 58. A method of identifying a compound capable of inhibiting the activity of a pheromone receptor which comprises contacting an appropriate amount of the purified pheromone receptor of claim 24 with an appropriated amount of the compound under conditions permitting the inhibition of a functional pheromone receptor response, the inhibition of the receptor response indicating that the compound is capable of
- 15 activating the activity of a pheromone receptor.
59. A method of claim 58, wherein the purified receptor is embedded in a lipid bilayer.
- 20 60. The compound identified by the method of claim 51, 52, 53, 54, 55, 56, 57, 58 or 59.
61. A method of claim 51, 52, 53, 54, 55, 56, 57, 58 or 59 wherein the compound is not previously known.
62. The compound identified by the method of claim 61.
- 25 63. A pharmaceutical composition comprising an effective amount of the compound of claim 60 and a pharmaceutically acceptable carrier.
64. A method for manipulating the maternal behavior of a female subject comprising administering effective

- 99 -

amount of the compound of claim 60 to the female subject.

- 5 65. A method for manipulating the social behavior of a subject comprising administering effective amount of the compound of claim 60 to the subject.
66. A method for manipulating the reproductive functions of a subject comprising administering effective amount of the compound of claim 60 to the subject.
- 10 67. A method for manipulating the reproductive behavior of a subject comprising administering effective amount of the compound of claim 60 to the subject.
68. A method for increasing the fertility of a subject comprising administering effective amount of the compound of claim 60 to the subject.
- 15 69. A method for manipulating hormonal secretion of a subject comprising administering effective amount of the compound of claim 60 to the subject.
70. A method of claim 69, wherein the hormone is the luteinizing hormone release hormone.
- 20 71. A method of claim 69, wherein the hormone is the luteinizing hormone.
72. A method of claim 69, wherein the hormone is the prolactin release hormone.
- 25 73. A method of claim 69, wherein the hormone is the prolactin.

- 100 -

74. A method for manipulating food intake rate of a subject comprising administering effective amount of the compound of claim 60 to the subject.
- 5 75. A method of 64, 65, 66, 67, 68, 69, 70, 71, 72 or 74 wherein the subject is a human.
76. A method of 64, 65, 66, 67, 68, 69, 70, 71, 72 or 74 wherein the subject is an animal.
- 10 77. A composition for manipulating the maternal behavior of a female subject comprising effective amount of the compound of claim 60 and an acceptable carrier.
78. A composition for manipulating the social behavior of a subject comprising effective amount of the compound of claim 60 and an acceptable carrier.
- 15 79. A composition for manipulating the reproductive functions of a subject comprising effective amount of the compound of claim 60 and an acceptable carrier.
80. A composition for manipulating the reproductive behavior of a subject comprising effective amount of the compound of claim 60 and an acceptable carrier.
- 20 81. A composition for increasing the fertility of a subject comprising effective amount of the compound of claim 60.
82. A composition for manipulating hormonal secretion of a subject comprising effective amount of the compound of claim 60 and an acceptable carrier.
- 25 83. A composition of claim 81, wherein the hormone is the

- 101 -

luteinizing hormone release hormone.

84. A composition of claim 81, wherein the hormone is the luteinizing hormone.
- 5 85. A composition of claim 81, wherein the hormone is the prolactin release hormone.
86. A composition of claim 81, wherein the hormone is the prolactin.
- 10 87. A composition for manipulating food intake rate of a subject comprising effective amount of the compound of claim 60 and an acceptable carrier.
88. A method of 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, or 87 wherein the subject is a human.
89. A method of 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, or 87 wherein the subject is an animal.
- 15 90. A compound of claim 60, wherein the compound is a polypeptide.
91. A transgenic nonhuman living organism expressing DNA encoding a vertebrate pheromone receptor.
- 20 92. A transgenic nonhuman living organism expressing DNA encoding the polypeptide of claim 90.
93. A transgenic animal of claim 91 or 92.
94. A transgenic nonhuman living organism comprising a homologous recombination knockout of the native pheromone receptor.

- 102 -

95. A transgenic animal of claim 94.

1/17

FIGURE 1A






FIGURE 1B



2/17



3/17

FIGURE 3A




FIGURE 3B




FIGURE 3C

FIGURE 3D

FIGURE 4A

I	II	
<p>VN1 MNNKNSRLYDSDMIRNTFFAEIGIGVVSANSLLLFNIFKLCIGQSRRLTDLPIGLLSLNLMLLHTAFIATDTIISWRGM</p> <p>VN2 MNNKNSRLHIDSMIRNTFFTEIGIGVVSANSLLLFNIFKFIHGQSRRLTDLPIGLLSLNLMLLIMACIATDIFISCRGM</p> <p>VN3 MNNKNSRVHTDSTIRNTFTSTIGIGILANSFLLLFNIFKFIHGQSRRLTDLPIGLLSLNLMLLIMACIATDIFISCRGM</p> <p>VN4 MNNKNDTCHVDTIMKITMFSEVSVGILANSILFFGHLCMLLGENCKPKPIHLYIASLSLTQLMLLITMGLIAADMFIISGGIM</p> <p>VN5 FSHLFMLFEKNRSKPIDLYIAFSLTQLMLLITIGLIAADMFIISGRGM</p> <p>VN6 MRRISTLYGVVDKQAIFFSEVVIIGISFNSIIFLFIHQFLLEALRLITDITISLALIHGMLTVMGFRAVDIFASGNVM</p> <p>VN7 MNNPVLVL-----QMTNMSYQGLVRTFPNSILFFAHLCMFFENRSKPIDLCIAFSLTQLMLLITMGLIAADMFIISGRGM</p>	<p>IV</p> <p>V</p> <p>VI</p> <p>VII</p>	<p>VN1 DDIICKSLLYLVRTFRGLSLGTSCLLSVLQAIILSPRSSCLAKFKHKPSHHISCAIILSSVLVYMFISSHLLVSLIATPNLT</p> <p>VN2 DDIICKSLLYLVRTFRGLSLGTSCLLSVLQAIILSPRSSCLAKFKHKPPHHIFCAMFLSVLYMFISSHLLVSLIATPNLT</p> <p>VN3 DDIICKFLVLYRSEFRGLSLGTTCLMSVLQAIILSPRSSCLAKFKHKSPHVSICAIISLSILYMFISSHLLVSLIATPNLT</p> <p>VN4 DSTSQSLIYLRHLSRGFTLSAACLNLNFMWITLSSKSSCLTKFKHNSPHHISGAFLLCCVLYMCFSSHLIISLIATPNLT</p> <p>VN5 DSTSQSLIYLRHLSRGFTLSAACLNLNFMWITLSSKSSCLTKFKHNSPHHISGAFLLCCVLYMCFSSHLIISLIATPNLT</p> <p>VN6 NDICKSLHLHRLRLRGLSLCATCLLSIFQAIILSPRSSCLAKFKHKSTQHSLSCLLVWAFYMSGTHYSFTIVADYNFS</p> <p>VN7 DDIICKSLLYLVRTFRGLSLGTSCLLSVLQAIILSPRSSCLAKFKHKPSHHISGAYLFFCVLYMFSHLLFVLVATSNLT</p>
<p>VN1 TNDFIHVTQVCSILPMSYLMQSMFSTLLAIRDVFLISLMLVSTIYVMVALLCRHKQTRHLQGTLSLSPKASPEQQRATRSILM</p> <p>VN2 TNDFIHVSQCSILPMSYLMQSMFSTLLAIRNVFLISLMLVSTIYVMVALLCRHKQTRHLQGTLSLSPKASPEQQRATRSILM</p> <p>VN3 TNNFMQVITQSCYIIPLSYLMQSMFSTLLAIRDISLSLMLVSTCYMEVLLCRHRNQIHLQGTLSLSPKASPEQQRATRSILM</p> <p>VN4 SDNEMVTKSCSFLPMYSRTSMFSTIIAIVREAFIIGMALSSGYLVAFLLWRHKQQAHLHSTIGLSKSSPEQQRATRSILM</p> <p>VN5 SDNEMVTKSCSFLPMYSRTSMFSTIIAIVREAFIIGMALSSGYLVAFLLWRHKQQAHLHSTIGLSKSSPEQQRATRSILM</p> <p>VN6 SRSLIFVTECIIIPMDYITRHLIFILGIFRDVSVFIIGMALSSGYLVAFLLWRHKQQAHLHSTIGLSKSSPEQQRATRSILM</p> <p>VN7 SDNEMVTKSCSFLPMYSRTSMFSTIIAIVREAFIIGMALSSGYLVAFLLWRHKQQAHLHSTIGLSKSSPEQQRATRSILM</p>	<p>VI</p> <p>VII</p>	<p>VN1 LMSLEVLMSVFDSDIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p> <p>VN2 LRSLEGLMSTFDSDIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p> <p>VN3 LMSLEVLMSIFDSIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p> <p>VN4 LMSLEVLMSIFDSIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p> <p>VN5 LMSLEVLMSIFDSIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p> <p>VN6 LMSLEVLMSIFDSIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p> <p>VN7 LMSLEVLMSIFDSIVCSRTMYLNDPISYSYQGLFVMIYATVSPFVIVTEKHIVNSIRSMGVKVHVECLNIP</p>

5/17

FIGURE 4B

I I
 I I I
 R. EP3B 59 SK2KKSFLCUCIGVUAEITDVG60LTSPVVJLVYLSQRREQL---DPSGRLC77FGLTMTVFGLSLEVASAMA 121
 VN2 43 GQ2SRLTDPIGLSLEINLMLIMACIATDIFSCRRDDIICKSLLYRI7RGLSLSTICL7SVLQQAII LS 105

6/17

FIGURE 4C

III

VN6 KCKSLAHLRLRLRGSLCAICLLSIFQATILSPRSSCLA
HG25 NISPVYRYRLMRGLSISTICLLSVLDAINLTPRSSRLA

IV


VN6 KSTQMSLCSLLVLEWAFYVMSGTHYSFTIVADYNFSSRSILIEVTESCIILPMDYITRDLFHILGIFRDVSFIGLMAISSGYMVALLC 215
HG25 RSSHFKPRCFELLLWVIMHISISGSFLVSTLPSKNVASNSVTIEVTSAGPISCFLGQTITMTIQDVSIL-qLMAFPFSGYMVILLCC

V

VI

VN6 RHRRKGADHLHRTSLSPKASPEQRAITRIILLMSFFVLWYCLDCTISASR 263
HG25 RHNRQSGHLHSINLSPKAPPDKRAIQSIELLLVSFFVFMCLFPFAALTLL

7/17



SUBSTITUTE SHEET (RULE 26)

8/17

FIGURE 6C




FIGURE 6B





FIGURE 6A



9/17

FIGURE 6F



FIGURE 6E





FIGURE 6D



10/17

FIGURE 7



11/17

FIGURE 8

TTTCGGCACGAGTTCACCTGCCCTCGAATTTCAATTTGAGTAAGTGACCAGC
AATGGAGTACAGAATCAGAAGATGGTTGGATCCCAGGCAGGCTGTGGGAGG
AGGAACTCTGGAAGTGCATGAGGAGTTTGAGCACCTGCCATGGAGTAGCTG
ATCTCTGAGGACCCCTCANCACAGGTCTGTGTTCTACATCAAGTGCATATT
TTTCCTAGGATATTCATTTCCGTAAGTCCTGAAATTACTTAATTTTTATAG
GAGTTCTCATATATGATGAATAAGAACAGCAGACTCTACACTGATTCTAA
CATAAGGAATACCTTTTTTCGCTGAAATTGGCATTGGAGTCTCAGCCAATAG
CCTCCTACTTCTCTTCAACATCTTCAAGTTAATTTGTGGGCAGAGGTCCAGA
CTCACTGACCTGCCCATTTGGTCTCTTGTCCTAATCAACTTACTTATGCTACT
GATGACGGCATTTCATAGCCACAGACACTTTTATTTCTTGGAGAGGGTGGGA
TGACATCATATGTAAATCCCTTCTCTACCTGTACAGAACTTTTAGAGGTCTC
TCTCTTTGTACCAGCTGCCTGTTGAGTGTCTGTCAGGCCATCATCCTCAGTCCC
AGAAGCTCCTGTTTAGCAAAGTTCAAACATAAGCCTTCCCATCACATCTCCT
GTGCCATTCTTTCTCTGAGTGTCTCTACATGTTTATTAGCAGTCACCTCTTA
GTATCCATCATTTGCCACCCCAAATTTGACCACGAATGACTTTATTCATGTTA
CTCAGTGGTGTCTATTCTACCCATGAGTTACCTCATGCAAAGCATGTTTTCT
ACACTGCTGGCCATCAGGGATGTCTTTCTTATTAGTCTCATGGTCTGTCAAC
ATGGTACATGGTGGCTCTCTTGTTGTAGGCACAGGAAACAGACCCGGCATCTT
CAGGGTACCAGCCTTTCCCCAAAAGCATCCCCAGAACAAAGGGCCACCCGTT
CCATCCTGATGCTCATGAGCTTATTTGTTCTGATGTCTGTCTTTGACAGCATT
GTCTGCAGCTCAAGAACTATGTATCTGAATGATCCAATATCTTATTCTTAT
CAACTATTTATGGTGCACATCTATGCCACAGTAAGCCCTTTTGTGTTTATTG
TCACTGAAAAACATATAGTTAACTCTTTGAGGTCCATGTGTGTGAAGGTGC
ATGAATGTTTGAATATTCCTTGATAGCAAGCTCCATTAAGAGGAGCCAAT
GTAAGCATCAGAACTGTCAATCATGGCGTGCTATGTGCTTTGGCATATGTG
AAATATGAAGTTGTTTTTCTGTTAAAATGATTTACTTTAACTGACGAGAT
GATGAACGTAACAGAAGATTAAACCACATCCCCTTTGATAT

12/17

FIGURE 9

GTGGATCCCCCGGGCTGCAGGAATTTCGGCACGAGCCGTGATTAAGGGACTTTG
AACTTTTCAAGGGATTTGGAGTTTTATGAAGAATTTGAAGATTTACAGAG
TTTACAGGAATGGAGCTGACCAGCCACTATGACATGCCTTATATCTCCAAG
AGCATAAATATAAGGCATGGCATGAGAGGACCAGCAGCCACTGTTCTCAT
ATATGATGAATAAGAACAGCAGAGTCCACACTGATTCTACCATAAGGAA
TACCTTCTCCACTGAAATTGGCATTGGAATCTTAGCCAACAGTTTCCTACTT
CTCTTCCACATCTTCAAGTTTATTCGTGGACAGAGGTCCAGACTCACTGACCT
GCCCCATTGGTCTCTTGTCCCTAATCCACCTACTGATGCTACTGATGGGGGCAT
TCATAGCCATAGACATTTTTATTTCTTGGAGGGGATGGGATGACATCATAT
GTAAATTCCTTGTCTACTTGTACAGAAGTTTTAGAGGTCTCTCTCTTGTAC
CACCTGCATGTTGAGTGTCTGCAGGCCATCACCTCAGCCCCAGAAGCTCTG
TTTAGCAAAGTTCAAACATAAGTCTCCCCATCACGTCTCCTGTGCCATTATT
TCGCTGAGCATCCTCTACATGTTCAATTAGCAGTCACCTCTTAGTATCCATCA
ATGCCACCCCCAATTTGACCACGAACAACCTTTATGCAAGTTACTCAGTCCTG
CTACATTATACCCTTGAGTTACCTCATGCAAAGCATGTTTTCTACACTTCTG
GCCATCAGAGATATCTCTCTTATTAGTCTCATGGTCCTCTCGACTTGTTACAT
GGAGGTCTCTTGTGTAGGCACAGGAATCAGATCCAGCATCTTCAAGGGACC
AACCTTTCCCCAAAAGCATCTCCAGAACAAGGGCCACACAGACCATCCTG
ATGCTCATGACCTTCTTTGTCCTAATGTCCATTTTCGACAGCATTGTCTCCTG
TTCAAGAACTATGTATCTGAATGATCCAACATCTTACTATATTCAAATAT
TTGTAGTGGACATCTATGCCACAGTCAGCCCTTTTGTGTTTATGAGCACTGG
AAAACATATAGTTAACTTTTTGAAGTCCATGTGTGTGAGGGTGAAGAATG
TTTGAATATTCATTAATGGACAAGATCCTTTAAGAGGAGCCAATGTAGTC
ATCAGAACTGTCAGTCATGGTGTGCTGTCTATGTGCTTTGGTAAATGTGAA
TCATGAAGTTGTTTTTCTGGTAAAATGATTTACTTTAACCAACTCATGATT
GTAAACATGTAACAGGAGATTAAACAATATCCCCTTCGGAAA

13/17

FIGURE 10

AATTCGGCACGAGCAAAGGCAGGGAAGATGCTCCACTGGGATGTCATGTCTC
TATGCTCCACAGTGGAAAAGTTGTACATTGTACAAACACTAAAATTACG
AATTGCTCACAGGCACTAAAAGCTTCCTTAATCCTGTGCAGGATCTCCTCAG
GTACAGAGTCCTCCTGATACGTCTATCTGGTCAGAGGAAAGAGCTGATCAG
TCATTAACAGAGCTGATTTGGTCCCTCCAAGGTCACATGACAAGGACTGTA
TGAGAAAACCAGCAGTGACATGTCTATAGAGATCATTCTGTGCCACACCCA
GCTCCATGTTTGGTTTGTGGTATTTGCTTCCTATCCACATACAATGAATAAA
GACAACACACTCCATGTTGACACAATCATGAAAATCACTATGTTCTCTGA
AGTGAGTGTTGGCATCTTAGCTAACAGTATCCTGTTTTTGGTCACCTGTGC
ATGCTCCTTGGAGAGAACAAGCCTAAGCCCATTCATCTCTACATTGCATCCT
TGTCCTAACACAACATAATGCTGCTTATAACTATGGGACTCATAGCTGCTG
ACATGTTTTATTTCTCAGGGGATATGGGATTCTACCTCATGCCAGTCCCTTAT
CTATTTGCACAGGCTTTCGAGGGGTTTTACCCTTAGTGCTGCCTGTCTGCTGA
ATGTCTTTTGGATGATCACTCTCAGTTCTAAAAAATCCTGTTTAACAAAGT
TTAAACATAACTCTCCCCATCACATCTCAGGTGCCTTTCTTCTCCTCTGTGTT
CTCTACATGTGTTTTAGCAGTCACCTTATTTTATCGATTATTGCTACCCCTA
ACTTGACCTCAGATAATTTTATGTATGTTACTAAGTCCTGTTCAATTTCTACC
CATGTGTTACTCCAGAACAAGCATGTTTTCCACAACAATTGCTGTCAGGGA
AGCCTTTTTTATCGGTCTCATGGCCCTGTCCAGTGGGTACCTGGTGGCTTTTCT
CTGGAGACACAGGAAGCAGGCCAGCATCTTCACAGCACCGGCCTTTCTTCA
AAGTCATCTCCAGAGCAAAGGGCCACCGAGACCATCCTGCTGCTTATGAGTT
TCTTTGTGGTTCTCTACATTTTGGAAAATGTTGTCTTCTACTCAAGGATGAA
GTTCAAGGATGGGTCAACATTCTACTGTGTCCAAATTATTGTGTCCCATAGC
TATGCCACTGTCAGCTCTTTTGTGTTTATTTTCACTGAAAAGCGTATGACTA
AGATATTGAGGTCAGTGTGTGCCAGAATAATAAATAATTGATTATTCAGT
GATGGGTATTGCCCCCTTAGAATAAACCATTACGTTGTCATCAGAGGTTTGG
GTCATGACATAATTGGGACATTCTCTGTCTTAAATTGATAAATGAAATTT
TCTTTTTTCTGTTAAAACTGTTTCCTTTGTGTGTGGATGCCCAATATATGA
AAGAAAATAAACACCATGTCCTCTTACATATCCAACCAAAAAAAAAA
AAA

14/17

FIGURE 11

TTTTTCCACCTCTTCATGCTCTTTGAAAAGAACAGATCTAAGCCCATTGA
TCTCTACATTGCTTTCTTATCCTTAACCCAACTAATGCTGCTTATAACTATT
GGACTTATAGCTGCAGACATGTTTATGTCTCGGGGGAGATGGGATTCTACCA
CATGCCAGTCCCTTATCTATTTGGACAGGCTTTTGAGGGGTTTTACCCTTTGT
GCTACCTGTCTGCTGAATGTCCTTTGGACCATCACTCTCAGTCCTAGAAGCTC
CTGTTTAACAACATTTAAACATAAATCTCCCCATCACATCTCAGGTGCCTT
TCTTTTCTTCTGTGTTCTCTATATATCTTTTGGCAGTCACCTCTTTTATCAA
CAATTGCTACCCCCAATTTGACTTCAGATAAATTTATGTATGTTACTAAAT
CCTGTTCAATTTCTACCCATGAGTTACTCCAGAACAAGCATGTTTTCCACACC
AATGGCCATCAGGGAAGCCCTTCTTATTGGTCTCATTGGCCTGTCCAGTGGGT
ACATGGTTGCTTTCCTATGGAGACACAAGAATCAGGCCCGGCATCTTCACAG
CACCAGCCTTTCTTCAAAAGTGTCCCCAGAGCAAAGGGCCACCAGGACCATC
ATGATTCTCATGAGCTTCTTTGTGGTTCTCTACATTTTGGAAAATGTTGTCT
TCTACTCTAGGATGACATTCAAGGATGGGTCAATGTTCTACTGTGTCCAAA
TTATTGTGTCCCATAGCTATGCCACCATCAGCCCTTTTGTGTTTATTTGCACA
GAAAAGCGTATAATTAACTTTGGGGGTCAATGTCTAGCAGAATAGTAA
GTATTTGATTACTCAGTGATGGATATGGTCCCTTAATATAAACCAATATG
TTGTCATAATAACTATGGATCATGACATATTGGGGACATTCTGTGTCTTAA
ATTTATAAAAAAAATTTTCTTTTTTTGTGTTTAATCTGTTTCCCTTGTGTG
TGGATGATAAGTATATAAAGGGAAATTAAACAGCGTGTCCCCTCAGATAT
CCAAAAAAAAAAAAAAAAAAAA

15/17

FIGURE 12

GGGCTGCAGGAATTCGGCACGAGTCAGAGTCCTTCCCTGCTATGTGTATCTGG
AGCCAGCGACTCTTCTATGGAGAGCAGCTGTGCAGGCAGGTGGTGGAGCGGA
AGAAGGCGTGCTGCTGTGACATCATCAAGATGCTGCCTAGCCCTGCGTCGCTG
CTCTTCTGAGGAAGCAGGAGACTGACCCCTGTGACAATGACTTGATGAGTCA
CTCTGTTGTCTACTTACCCTAGTTCTTTGTCCCATAACAATGAGGAGAATCAG
CACACTGTATGGAGTTGTTGACAAGCAAGCTATATTTTTCTCTGAAGTAGT
CATCGGGATCTCATTCAACAGTATCCTCTTCCCTCTTCCACATCTTTCAGTTCC
TTCTTGAGCGTAGGCTCCGGATCACTGACCTGATCATCAGTCTCTTGGCCCTC
ATCCACCTTGGGATGCTAACAGTCATGGGATTGAGAGCTGTTGATATTTTTG
CATCTCAGAATGTGTGGAATGACATCAAATGCAAATCCCTTGCCCACTTAC
ACAGACTTTTGAGGGGCTCTCTCTTTGTGCTACCTGTCTGCTGAGTATCTTCC
AGGCCATCACCTTAGCCCCAGAAGCTCCTGTTTAGCAAAGTTCAAATATA
AATCCACACAGCACAGCCTGTGTTCCCTTCTTGTGCTCTGGGCTTCTACATGT
CCTGTGGTACTCACTACTCCTTCACCATCGTTGCTGACTACAACCTTCTCTTAC
GCAGTCTCATATTTGTCACTGAATCCTGCATTATTTTACCCATGGATTACAT
CACCAGGGATTTATTTTTCATATTGGGGATATTTTCGGGATGTGTCCTTCATA
GGTCTCATGGCCCTCTCCAGCGGGTACATGGTGGCCCTCTTGTGCAGACACAGG
AAACAGGCCCAGCATCTTCACAGGACCAGCCTTTCTCCAAAAGCATCCCCAG
AGCAAAGGGCCACCAGGACCATCCTGTTGCTCATGAGCTTCTTTGTGTTGAT
GTACTGCTTGGACTGCACCATATCCGCCTCCAGACTTATGCACAACGGTGAA
CCAATCCACCACAGTATTCAGATGATGGTCTCCAATAGCTATGCCACCCTCA
GCCCTTTGCTGTTAATTGTTACTGAAAATCGAATTAGTAGGTTTTTGAAGT
CCTTGCTAGGAAGGACAGTAGATGCTTAAGTATTGAGGGGAGGCAGGCCCA
CTAAAGGAGCCAATATGCTAGCTACTGAATAATGAATCCTGGCCTAGTCCT
CATGCAATCCTGAACAAATTAATACATGACTCATGCTTCGTTAAACCTGCT
TCTTTTGAAATGTGTATTACCAACACCTGTAGATATTTGAGTCAAATTTCT
TCATGTGTATTTCTTCTCAGTGTGAGTGGGACATCTGTGACACTTTCACA
GATTAGGGTAACTTGTGCACTTATCAATAAGCTAAAGTGTACAGCACATT
TACTAAGCCAATTATCTCAACAGTTTGTCTTCTACCCAATTAAATATGTA
AATGTTACCACCAAAAAAAAAAAAAAAAAA

16/17

FIGURE 13

TTGGGGTAAAACGGCTCGATGACTTCCACATGTTTTGCCATGGCAGAATCTG
CTCCATGCGGGACAAGAAAATCTCTTTTCTGGTCTGACGGNGCTTACTGCTG
AATTCAGTGTGCGCGAAGGTAAGTTGATGACTCATGATGAACCCTGTTCTA
TGGCTCCAGATGACAAACATGATCTCATATCAGGGACTTGTTTCGCACCTTCC
CTAACAGTATCCTGTTTTTTGCCCACCTCTGCATGTTCTTTGAAGAGAACAG
GTCTAAGCCCATTGATCTGTGCATTGCTTTCTTATCCTTAACCCAACTAATG
CTGCTTGTAACATATGGGACTCATAGCTGCAGACATGTTTATGGCTCAGGGGA
TATGGGATATTACCACATGCAGGTCCCTTATCTATTTTCACAGACTTTTGAG
GGGTTTCAACCTTTGTGCTGCCTGTCTACTGCATATCCTTTGGACCTTCACTCT
CAGTCCTAGAAGCTCCTGTTTAACAAAGTTTAAACATAAATCTCCCCATCA
CATCTCAGGTGCCTATCTTTTCTTCTGTGTTCTCTATATGTCCTTTAGCAGTC
ACCTCTTTGTATTGGTCATTGCTACCTCCAATTTAACCTCAGATCATTTTAT
GTATGTTACTCAGTCCTGCTCACTTCTACCCATGAGTTACTCCAGAACAAGC
ACGTTTTCTTACTGATGGTCACCAGGGAAGTCTTTCTTATCAGTCTCATGGC
CCTGTCCAGTGGGTACATGGTGACTCTCCTATGGAGGCACAAGAAGCAGGCC
GAGCATCTTCACAGCACCAGACTTTCTTCAAAAGCATCCCCACAGCAAAGGG
CCACCAGGACCATCCTGCTGCTTATGACCTTCTTTGTGGTTTTCTACATTTTA
GGCACTGTTATCTTCCACTCAAGGACTAAGTTCAAGGATGGGTCAATCTTCT
ACTGTGTCCAAATTATTGTGTCCCATAGCTATGCCACTATCAGCCCATTGT
GTTTGTTTTTTCTGAAAAGCGCATAATCAAGTTTTTTAGATCAATGTGTGG
CAGAATAGTAAATACTTGATTATTCAGTATGAGTATGGGTCATGAATAT
AGTCTAGTAAATTGTGATCAGAGTTATGGCTCATGACATATTA AAAACAT
TCTCTAATTTAAGTTTAACATATAAAATTATCTTATTTCTCTTAAATGTG
TTTACTTTGTGTGTATTAAAAGTATGTAAGATAATTAATCCCCAAAT
ACACCTTTTTTTCAAATTA AAAAAA

17/17

FIGURE 14

1 AAACATAAGT CCAGTTATCT ACAGGTACAG GTTGATGAGA GGCTCTCCA TTTCCACCAC
61 CTGCC'TGTTG AGTGTCCTCC AGGCCATCAA CCTCACCCCA AGGAGCTCCC GTTGTGGCAAT
121 GTTCAGAGAT CCTCACATCA CAAACCGCGT TGC'TTCTCT TGCTGTGGGT CTTCCACATA
181 TCCATTAGTG GAAGCTTCTT AGTCTCCACT CTTCCTCCA AAAATGTTGC CTCAAATAGT
241 GTTACATTTG TCACTCAATC CTGCTCTGCT GGGCCCTGA GTTGCTTCT TGGGCAGACA
301 ATTTTCACAC TGATGACATT TCAGGATGTC TCCTTGCAGC TCATGGCCCC CTTCAGTGA
361 TACATGGTGA TTC'TCTTGT CAGGCATAAC AGGCAGTCTC AGCATCTTCA TAGTATCAAC
421 CTTTCTCCAA AAGCACCCCC AGATAAAAGG GCCATCCAGA GCATTCTTTT GCTCGTGAGT
481 TTCTTTGTGT TCATGTGCCT TTTCCCATTT GCTGCCTTAA CACTTCTGTC

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16637

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 15/00

US CL :800/2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 800/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog
pheromone receptors, vertebrate, transgenic, behavior

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	Cell, Volume 83, issued 20 October 1995, Troemel et al., "Divergent seven transmembrane receptors are candidate chemosensory receptors in <i>C. elegans</i> ", pages 207-218, see entire reference.	1-95
Y	Proceedings of the National Academy of Sciences, Volume 84, issued March 1987, Rogers et al., "Molecular cloning and sequencing of a cDNA for olfactory marker protein", pages 1704-1708, see entire reference.	1-24, 29-50
Y	Cell, Volume 79, issued 16 December 1994, Vassar et al., "Topographic organization of sensory projections to the olfactory bulb", pages 981-991, see entire reference.	25,51-90

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A*	document member of the same patent family
* * document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 JANUARY 1997

Date of mailing of the international search report

12 FEB 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SUZANNE ZISKA, PH.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16637

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Cell, Volume 65, issued 05 April 1991, Buck et al., "A novel multigene family may encode odorant receptors: A molecular basis for odor recognition", pages 175-187, see entire reference.	51-90
X,P	Cell Volume 83, issued 20 October 1995, Dulac et al., "A novel family of genes encoding putative pheromone receptors in mammals", pages 195-206, see entire reference.	1-25,29-46
Y	The EMBO Journal, Volume 12, No. 4., issued 1993, Baldwin et al., "The probable arrangement of the helices in G protein-coupled receptors", pages 1693-1703, see entire reference.	51-90
Y	Neuron, Volume 13, issued October 1994, Shepherd, G., "Discrimination of molecular signals by the olfactory receptor neuron", pages 771-790, see entire reference.	26-28, 51-90
Y	Advances in Genetics, Volume 24, issued 1987, Scangos et al., "Gene transfer into mice", pages 285-321, see entire reference.	91-95

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16637

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16637

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-24 and 29-30, drawn to an isolated nucleic acid molecule encoding a vertebrate pheromone receptor, vectors containing the nucleic acid molecule, host cells transformed with the vector, methods of producing the polypeptide, and methods for identifying cDNA inserts encoding the receptors. This group encompasses the first named product and the first named methods of using and making the first named product.

Group II, claim(s) 25, drawn to a pheromone receptor.

Group III, claim(s) 26-28, drawn to antibodies capable of binding to the pheromone receptor.

Group IV, claims 51-53, drawn to methods of identifying a compounds capable of specifically binding to a vertebrate pheromone receptor.

Group V, claims 54-63, drawn to methods of identifying a compounds capable of activating or inhibiting the activity of a pheromone receptor.

Group VI, claims 64-90, drawn to a method for manipulating the behavior of a female subject comprising administering effective amounts of the compound. Group VII, claims 91-95, drawn to a transgenic non-human organism.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature is the nucleic acid sequence encoding the pheromone receptor. PCT rule 13 does not permit multiple products and methods within a single invention.